<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1409-0015</journal-id>
<journal-title><![CDATA[Medicina Legal de Costa Rica]]></journal-title>
<abbrev-journal-title><![CDATA[Med. leg. Costa Rica]]></abbrev-journal-title>
<issn>1409-0015</issn>
<publisher>
<publisher-name><![CDATA[Asociación Costarricense de Medicina Forense]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1409-00152022000100037</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Análisis médico legal de la toxicomanía por MDMA : reporte de caso]]></article-title>
<article-title xml:lang="en"><![CDATA[Medical-legal relationship of MDMA drug addiction: case report]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vargas Torres]]></surname>
<given-names><![CDATA[Edgar Andrés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Costa Rica Departamento de Medicina Legal del Poder Judicial ]]></institution>
<addr-line><![CDATA[Heredia ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2022</year>
</pub-date>
<volume>39</volume>
<numero>1</numero>
<fpage>37</fpage>
<lpage>75</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S1409-00152022000100037&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S1409-00152022000100037&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S1409-00152022000100037&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El análisis por toxicomanía representa un proceso común solicitado por la Autoridad Judicial para determinar si un usuario presenta hallazgos compatibles con el uso de una droga a nivel clínico, componentes histológicos, patológicos y toxicológicos que puedan generar su uso. Es necesario destacar las limitaciones del ambiente clínico donde se pueden generar múltiples hallazgos, y de la toxicología forense donde a pesar de la especificidad a la que se asocia; también se encuentra limitada por la capacidad de sus equipos tecnológicos. La resonancia magnética nuclear cuantitativa de hidrógeno representa grandes ventajas al demostrar la presencia de una droga ilegal, así como la posibilidad de disminuir costos y tiempo laboral. El uso del MDMA como tratamiento con una reciente aprobación para un estudio de fase III por la FDA, también requiere que se valore el motivo de su uso, por lo que para realizar un análisis médico legal se contemplaron diversos elementos de juicio a fin de satisfacer la evaluación sobre la toxicomanía por MDMA en un usuario que presentó un tejido granular blanco tipo polvo en la sección distal del tabique nasal y negó el consumo de metanfetaminas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The analysis for drug addiction represents a common process requested by the Judicial Authority to determine if a user presents findings compatible with the use of a drug at a clinical level, histological, pathological and toxicological components that may generate its use. It is necessary to highlight the limitations of the clinical environment where multiple findings can be generated, and of forensic toxicology where despite the specificity to which it is associated; it is also limited by the capacity of its technological equipment. Quantitative hydrogen nuclear magnetic resonance represents great advantages when demonstrating the presence of an illegal drug, as well as the possibility of reducing costs and labor time. The use of MDMA as a treatment with a recent approval for a phase III study by the FDA, also requires that the reason for its use be assessed, therefore, in order to carry out a legal medical analysis, various elements of judgment were considered in order to satisfy evaluation of MDMA drug addiction in a user who presented with white powder-like granular tissue in the distal section of the nasal septum and denied the use of methamphetamine.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[MDMA]]></kwd>
<kwd lng="es"><![CDATA[N-Metil-3,4 metilendioxianfetamina]]></kwd>
<kwd lng="es"><![CDATA[Medicina Legal]]></kwd>
<kwd lng="es"><![CDATA[Estimulantes del Sistema Nervioso Central]]></kwd>
<kwd lng="es"><![CDATA[Trastornos Relacionados con Sustancias]]></kwd>
<kwd lng="es"><![CDATA[Drogas de Diseño]]></kwd>
<kwd lng="en"><![CDATA[MDMA]]></kwd>
<kwd lng="en"><![CDATA[N-Methyl-3,4-methylenedioxyamphetamine]]></kwd>
<kwd lng="en"><![CDATA[Legal medicine (Forensic Medicine)]]></kwd>
<kwd lng="en"><![CDATA[Central Nervous System Stimulants]]></kwd>
<kwd lng="en"><![CDATA[Substance-Related Disorders]]></kwd>
<kwd lng="en"><![CDATA[Designer Drugs]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vargas Alvarado]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<source><![CDATA[Medicina Legal. Capítulo 35, Farmacodependencia.]]></source>
<year>2017</year>
<edition>Sexta</edition>
<page-range>433-62</page-range><publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Trillas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shulgin]]></surname>
<given-names><![CDATA[AT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The background and chemistry of MDMA]]></article-title>
<source><![CDATA[J Psychoactive Drugs]]></source>
<year>1986</year>
<volume>18</volume>
<page-range>291-304.</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ridpath]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Driver]]></surname>
<given-names><![CDATA[C.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Kunins]]></surname>
<given-names><![CDATA[H.V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Illnesses and deaths among persons attending an electronic dance-music festival - New York City, 2013.]]></article-title>
<source><![CDATA[MMWR Morb Mortal Wkly Rep]]></source>
<year>2014</year>
<page-range>1195-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="book">
<source><![CDATA[Meyler&#8217;s Side Effects of Drugs. Capítulo Methylendioxy-metamfetamine.]]></source>
<year>2016</year>
<edition>Décimo sexta</edition>
<page-range>917-52</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Britt]]></surname>
<given-names><![CDATA[G.C.]]></given-names>
</name>
<name>
<surname><![CDATA[McCance-Katz]]></surname>
<given-names><![CDATA[E.F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A brief overview of the clinical pharmacology of &#8220;club drugs&#8221;.]]></article-title>
<source><![CDATA[Subst Use Misuse]]></source>
<year>2005</year>
<volume>40</volume>
<page-range>1189-201</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalant]]></surname>
<given-names><![CDATA[Harold]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The pharmacology and toxicology of &#8220;ecstasy&#8221; (MDMA) and related drugs.]]></article-title>
<source><![CDATA[CMAJ]]></source>
<year>2001</year>
<volume>165</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>917-28</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<collab>Observatorio Europeo de las Drogas y las Toxicomanías</collab>
<source><![CDATA[Informe Europeo sobre Drogas Tendencias y novedades. Luxem-burgo]]></source>
<year>2021</year>
<publisher-name><![CDATA[Oficina de Publicaciones de la Unión Europea.]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sumnall]]></surname>
<given-names><![CDATA[H.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Cole]]></surname>
<given-names><![CDATA[J.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Jerome]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy]]></article-title>
<source><![CDATA[J Psychopharmacol]]></source>
<year>2006</year>
<volume>20</volume>
<page-range>670-82</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parrott]]></surname>
<given-names><![CDATA[A.C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chronic tolerance to recreational MDMA (3,4-methlenedioxymethamphetamine) or ecstasy]]></article-title>
<source><![CDATA[J Psychopharmacol]]></source>
<year>2005</year>
<volume>19:</volume>
<page-range>71-83</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McGuire]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Fahy]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chronic paranoid psychosis after misuse of MDMA (&#8220;ecstasy&#8221;)]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>1991</year>
<volume>302</volume>
<page-range>697</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCann]]></surname>
<given-names><![CDATA[U.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Ricaurte]]></surname>
<given-names><![CDATA[G.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Major metabolites of (+/&#8722;)3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons]]></article-title>
<source><![CDATA[Brain Res]]></source>
<year>1991</year>
<volume>545</volume>
<page-range>279-82</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Climko]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Roehrich]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sweeney]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Razi]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ecstacy [sic]: a review of MDMA and MDA.]]></article-title>
<source><![CDATA[Int J Psychiatry Med]]></source>
<year>1987</year>
<volume>16</volume>
<page-range>359-72</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peroutka]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Newman]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subjective effects of 3,4-methylenedioxy-methamphetamine in recreational users.]]></article-title>
<source><![CDATA[Neu-ropsychopharmacology]]></source>
<year>1988</year>
<volume>1</volume>
<page-range>273-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tolbert]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subjective reports of the effects of MDMA in a clinical setting.]]></article-title>
<source><![CDATA[J Psychoactive Drugs]]></source>
<year>1986</year>
<volume>18</volume>
<page-range>319-27</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gawin]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
<name>
<surname><![CDATA[Ellinwood]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cocaine and other stimulants. Actions, abuse, and treatment.]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1988</year>
<volume>318</volume>
<page-range>1173-82</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Diorio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tannenbaum]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Caldji]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Maternal care, hippocampal glucocorticoid receptor expression and hy-pothalamic-pituitary-adrenal responses to stress]]></article-title>
<source><![CDATA[Science]]></source>
<year>1997</year>
<volume>277</volume>
<page-range>1659-62</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Diorio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Day]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Maternal care, hippocampal synaptogenesis and cognitive development in rats.]]></article-title>
<source><![CDATA[Nat Neurosci]]></source>
<year>2001</year>
<volume>2</volume>
<page-range>799-806</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Kuhar]]></surname>
<given-names><![CDATA[MJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency of maternal licking and grooming correlates negatively with vulnerability to cocaine and alcohol use in rats]]></article-title>
<source><![CDATA[Pharmacol Biochem Beh]]></source>
<year>2008</year>
<volume>90</volume>
<page-range>497-500.</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruiz Contreras]]></surname>
<given-names><![CDATA[Alejandra E]]></given-names>
</name>
<name>
<surname><![CDATA[Méndez Días]]></surname>
<given-names><![CDATA[Mónica]]></given-names>
</name>
<name>
<surname><![CDATA[Prieto Gómez]]></surname>
<given-names><![CDATA[Bertha]]></given-names>
</name>
<name>
<surname><![CDATA[romano]]></surname>
<given-names><![CDATA[Antonio]]></given-names>
</name>
<name>
<surname><![CDATA[Caynas]]></surname>
<given-names><![CDATA[Seraid]]></given-names>
</name>
<name>
<surname><![CDATA[Próspero García]]></surname>
<given-names><![CDATA[Oscar]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El cerebro, las drogas y los genes.]]></article-title>
<source><![CDATA[Salud Ment]]></source>
<year>2010</year>
<volume>33</volume>
<numero>6</numero>
<issue>6</issue>
<publisher-loc><![CDATA[México ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aron]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Fletcher]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Bullmore]]></surname>
<given-names><![CDATA[ET]]></given-names>
</name>
<name>
<surname><![CDATA[Sahakian]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans.]]></article-title>
<source><![CDATA[Nat Neurosci]]></source>
<year>2003</year>
<volume>6</volume>
<page-range>115-6</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network : 2011: National Estimates of Drug-Related Emergency Department Visits]]></article-title>
<source><![CDATA[HHS Publication]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schuster]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Lieb]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Lamertz]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Wittchen]]></surname>
<given-names><![CDATA[H.U.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is the use of ecstasy and hallucinogens increasing? Results from a commu-nity study]]></article-title>
<source><![CDATA[Eur Addict Res]]></source>
<year>1998</year>
<volume>4</volume>
<page-range>75-82</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maxwell]]></surname>
<given-names><![CDATA[J.C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Party drugs: properties, prevalence, patterns and problems.]]></article-title>
<source><![CDATA[Subst Use Misuse]]></source>
<year>2005</year>
<volume>40</volume>
<page-range>1203-40</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Banta-Green]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Goldbaum]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Kingston]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Golden]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Harruff]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Logan]]></surname>
<given-names><![CDATA[B.K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of MDMA and associated club drugs in the Seattle area]]></article-title>
<source><![CDATA[Subst Use Misuse]]></source>
<year>2005</year>
<volume>40</volume>
<page-range>1295-315</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soellner]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<source><![CDATA[Club drug use in Germany. Subst Use Misuse 2005]]></source>
<year></year>
<volume>40</volume>
<page-range>1279-93</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[Jhon A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ectasy and the dance of death.]]></article-title>
<source><![CDATA[Br. Med. J]]></source>
<year>1992</year>
<volume>305</volume>
<page-range>5-6</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ecstasy and the dance of death]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>1992</year>
<volume>305</volume>
<page-range>5-6.</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sherlock]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Wolff]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hay]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Conner]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department]]></article-title>
<source><![CDATA[J Accid Emerg Me]]></source>
<year>1999</year>
<volume>16</volume>
<page-range>194-7</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MDMA - nonmedical use and intoxication]]></article-title>
<source><![CDATA[J Psychoactive Drugs]]></source>
<year>1986</year>
<volume>18</volume>
<page-range>349-54.</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vollenweider]]></surname>
<given-names><![CDATA[FX]]></given-names>
</name>
<name>
<surname><![CDATA[Gamma]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Liechti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Huber]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psychological and cardiovascular effects and short-term sequelae of MDMA (&#8220;ecstasy&#8221;) in MDMA-naive healthy volunteers.]]></article-title>
<source><![CDATA[Neuropsychopharmacology]]></source>
<year>1998</year>
<volume>19</volume>
<page-range>241-51</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wollina]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
<name>
<surname><![CDATA[Kammler]]></surname>
<given-names><![CDATA[H.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Hesselbarth]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Mock]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Bosseckert]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ecstasy pimples-a new facial dermatosis]]></article-title>
<source><![CDATA[Dermatology]]></source>
<year>1998</year>
<volume>197:</volume>
<page-range>171-3</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Foley]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guttate psoriasis following ecstasy ingestion.]]></article-title>
<source><![CDATA[Australas J Dermatol]]></source>
<year>2004</year>
<volume>45</volume>
<page-range>167-9</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[M.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Belson]]></surname>
<given-names><![CDATA[M.G.]]></given-names>
</name>
<name>
<surname><![CDATA[Longwater]]></surname>
<given-names><![CDATA[A.B.]]></given-names>
</name>
<name>
<surname><![CDATA[Olson]]></surname>
<given-names><![CDATA[K.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[M.A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MDMA (ecstasy)-related hyperthermia.]]></article-title>
<source><![CDATA[J Emerg Med]]></source>
<year>2005</year>
<volume>29</volume>
<page-range>451-454.</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harry]]></surname>
<given-names><![CDATA[R.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Sherwood]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Wendon]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Detection of myocardial damage and cardiac dysfunction following ecstasy ingestion.]]></article-title>
<source><![CDATA[Clin Intensive Care]]></source>
<year>2001</year>
<volume>12</volume>
<page-range>85-7</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bassi]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Ritto]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ecstasy and chest pain due to coronary artery spasm.]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2005</year>
<volume>99</volume>
<page-range>485-7</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Madhok]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Boxer]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Chowdhury]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial fibrillation in an adolescent-the agony of ecstasy]]></article-title>
<source><![CDATA[Pediatr Emerg Care]]></source>
<year>2003</year>
<volume>19</volume>
<page-range>348-9</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duflou]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Mark]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aortic dissection after ingestion of &#8216;ecstasy&#8217; (MDMA).]]></article-title>
<source><![CDATA[Am J Forensic Med Pathol]]></source>
<year>2000</year>
<volume>21</volume>
<page-range>261-3</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[A.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Drew]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Rees]]></surname>
<given-names><![CDATA[G.M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Ecstasy&#8221; induced pneumomediastinum]]></article-title>
<source><![CDATA[J R Soc Med]]></source>
<year>1993</year>
<volume>86</volume>
<page-range>232-3</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rejali]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Glen]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Odom]]></surname>
<given-names><![CDATA[N.:]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pneumomediastinum following Ecstasy (methylenedioxymetamphetamine, MDMA) ingestion in two people at the same &#8216;rave&#8217;.]]></article-title>
<source><![CDATA[J Laryngol Otol]]></source>
<year>2002</year>
<volume>116</volume>
<page-range>75-6</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[C.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Chau]]></surname>
<given-names><![CDATA[L.F.]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[C.H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Massive spontaneous haemopneumothorax and ecstasy abuse]]></article-title>
<source><![CDATA[Hong Kong J Emerg Med]]></source>
<year>2004</year>
<volume>11</volume>
<page-range>94-7</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brazier]]></surname>
<given-names><![CDATA[W.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Dhariwal]]></surname>
<given-names><![CDATA[D.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Patton]]></surname>
<given-names><![CDATA[D.W.]]></given-names>
</name>
<name>
<surname><![CDATA[Bishop]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ecstasy related periodontitis and mucosal ulceration-a case report]]></article-title>
<source><![CDATA[Br Dent J]]></source>
<year>2003</year>
<volume>194</volume>
<page-range>197-9</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duxbury]]></surname>
<given-names><![CDATA[A.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ecstasy-dental implications.]]></article-title>
<source><![CDATA[Br Dent J]]></source>
<year>1993</year>
<volume>175</volume>
<page-range>38</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brncic]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Kraus]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Viskovic]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Mijandrusic-Sincic]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Vlahovic-Palcevski]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[3,4-methylenedioymethamphetamine(MDMA): an important cause of acute hepatitis.]]></article-title>
<source><![CDATA[Med Sci Monit]]></source>
<year>2006</year>
<volume>12</volume>
<page-range>CS107-9</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kwon]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Zaritsky]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Dharnidharka]]></surname>
<given-names><![CDATA[V.R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transient proximal tubular renal injury following ecstasy ingestion.]]></article-title>
<source><![CDATA[Pediatr Nephrol]]></source>
<year>2003</year>
<volume>18</volume>
<page-range>820-2</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brody]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Krause]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Veit]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Rau]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular autonomic dysregulation in users of MDMA ("Ecstasy").]]></article-title>
<source><![CDATA[Psychopharmacology Berl]]></source>
<year>1998</year>
<volume>136</volume>
<page-range>390-3</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrett]]></surname>
<given-names><![CDATA[P.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[G.T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Ecstasy&#8221; ingestion: a case report of severe complications]]></article-title>
<source><![CDATA[J R Soc Med]]></source>
<year>1993</year>
<volume>86</volume>
<page-range>233-4</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Finsterer]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Stollberger]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Steger]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Kroiss]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long lasting impaired cerebral blood flow after ecstasy intoxication.]]></article-title>
<source><![CDATA[Psychiatry Clin Neurosci]]></source>
<year>2003</year>
<volume>57</volume>
<page-range>221-5</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yin Foo Lee]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Wooi Kee Gong]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Vrodos]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Patrick Brophy]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8216;Ecstasy&#8217;-induced subarachnoid haemorrhage: an under-reported neurological complication?.]]></article-title>
<source><![CDATA[J Clin Neurosci]]></source>
<year>2003</year>
<volume>10</volume>
<page-range>705-7</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[James N]]></surname>
<given-names><![CDATA[George]]></given-names>
</name>
<name>
<surname><![CDATA[Adam Cuker]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<source><![CDATA[Microangiopatía inducidad por drogas]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pacifici]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Zuccaro]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Farre]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Pichini]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Di Carlo]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Roset]]></surname>
<given-names><![CDATA[P.N.]]></given-names>
</name>
<name>
<surname><![CDATA[Ortuno]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Segura]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[de la Torre]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[mmunomodulating properties of MDMA alone and in combination with alcohol: a pilot study.]]></article-title>
<source><![CDATA[Life Sci]]></source>
<year>1999</year>
<volume>65</volume>
<page-range>L309-16</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zwick]]></surname>
<given-names><![CDATA[O.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Fischer]]></surname>
<given-names><![CDATA[D.H.]]></given-names>
</name>
<name>
<surname><![CDATA[Flanagan]]></surname>
<given-names><![CDATA[J.C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Ecstasy&#8221; induced immunosuppression and herpes zoster ophthalmicus.]]></article-title>
<source><![CDATA[Br J Ophthalmol]]></source>
<year>2005</year>
<volume>89</volume>
<page-range>923-4</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verhaert]]></surname>
<given-names><![CDATA[L.L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Methaemoglobinemia induced by MDMA?.]]></article-title>
<source><![CDATA[Case Rep Pulmonol]]></source>
<year>2011</year>
<page-range>1-3</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[A.P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyponatraemia, water intoxication and 'ecstasy'.]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>1997</year>
<volume>23</volume>
<page-range>1289</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Watson]]></surname>
<given-names><![CDATA[I.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Serlin]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Moncur]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Tames]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute hyponatraemia.]]></article-title>
<source><![CDATA[Postgrad Med J]]></source>
<year>1997</year>
<volume>73</volume>
<page-range>443-4</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hartung]]></surname>
<given-names><![CDATA[T.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Schofield]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Short]]></surname>
<given-names><![CDATA[A.I.]]></given-names>
</name>
<name>
<surname><![CDATA[Parr]]></surname>
<given-names><![CDATA[M.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, &#8220;ecstasy&#8221;) ingestion.]]></article-title>
<source><![CDATA[QJM]]></source>
<year>2002</year>
<volume>95</volume>
<page-range>431-7</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parr]]></surname>
<given-names><![CDATA[M.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Low]]></surname>
<given-names><![CDATA[H.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Botterill]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyponatraemia and death after "ecstasy" ingestion.]]></article-title>
<source><![CDATA[Med J Aust]]></source>
<year>1997</year>
<volume>166</volume>
<page-range>136-137.</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morán Chorro]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Marruecos Sant]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado Martín]]></surname>
<given-names><![CDATA[M.O.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hiponatremia, edema cerebral y muerte encefalica en una intoxicación aguda por 3,4 metilendioximetanfetamina.]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2005</year>
<volume>124</volume>
<page-range>198</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aramendi]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Manzanares]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Encefalopatia hiponatrémica y muerte cerebral en la intoxicación por éxtasis (3,4-metilendioximetanfetamina).]]></article-title>
<source><![CDATA[Med Intensiva]]></source>
<year>2010</year>
<volume>34</volume>
<page-range>634-5</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raviña]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Quiroga]]></surname>
<given-names><![CDATA[J.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Raviña]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyperkalemia in fatal MDMA (&#8216;ecstasy&#8217;) toxicity.]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2004</year>
<volume>93</volume>
<page-range>307-8</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riva]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Morana]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Cerri]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Gerevini]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Amadio]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Formaglio]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Comi]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Comola]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Del Carro]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute myelopathy selectively involving lumbar anterior horns following intranasal insufflations of ecstasy and heroin]]></article-title>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>2007</year>
<volume>78</volume>
<page-range>908-9</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mintzer]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Hickenbottom]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Gilman]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Parkinsonism after taking ecstasy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1999</year>
<volume>340</volume>
<page-range>1443</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schroeder]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Brieden]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bilateral sixth nerve palsy associated with MDMA (&#8220;ecstasy&#8221;) abuse]]></article-title>
<source><![CDATA[Am J Ophthalmol]]></source>
<year>2000</year>
<volume>129</volume>
<page-range>408-9</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Beal]]></surname>
<given-names><![CDATA[MF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2006</year>
<volume>443</volume>
<page-range>787-95</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Newton]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Naiberg]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Goldstein]]></surname>
<given-names><![CDATA[BI.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oxidative stress and cognition amongst adults without dementia or stroke: implications for mechanistic and therapeutic research in psychiatric disorders]]></article-title>
<source><![CDATA[Psychiatry Res]]></source>
<year>2015</year>
<volume>227</volume>
<page-range>127-34</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robert K Hoffman]]></surname>
<given-names><![CDATA[MD.]]></given-names>
</name>
</person-group>
<source><![CDATA[Intoxicación por MDMA (éxtasis).]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B66">
<label>66.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mueller]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Korey]]></surname>
<given-names><![CDATA[WS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Death by "ecstasy": the serotonin syndrome?]]></article-title>
<source><![CDATA[Ann Emerg Med]]></source>
<year>1998</year>
<volume>32</volume>
<page-range>377</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bodner]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Lynch]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kahn]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serotonin syndrome]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>1995</year>
<volume>45</volume>
<page-range>219</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baylen]]></surname>
<given-names><![CDATA[C.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenberg]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A review of the acute subjective effects of MDMA/ecstasy]]></article-title>
<source><![CDATA[Addiction]]></source>
<year>2006</year>
<volume>101</volume>
<page-range>933-47</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vollenweider]]></surname>
<given-names><![CDATA[F.X.]]></given-names>
</name>
<name>
<surname><![CDATA[Liechti]]></surname>
<given-names><![CDATA[M.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Gamma]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Greer]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Geyer]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute psychological and neurophysiological effects of MDMA in humans]]></article-title>
<source><![CDATA[J Psychoactive Drugs]]></source>
<year>2002</year>
<volume>34</volume>
<page-range>171-184.</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subjective reports on the effects of the MDMA (&#8216;ecstasy&#8217;) experience in humans.]]></article-title>
<source><![CDATA[Prog Neuropsychopharmacol Biol Psychiatry]]></source>
<year>1995</year>
<volume>19</volume>
<page-range>1137-45</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vecellio]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Schopper]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Modestin]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuropsychiatric consequences (atypical psychosis and complex-partial seizures) of ecstasy use: possible evidence for toxicity-vulnerability predictors and implications for preventative and clinical care]]></article-title>
<source><![CDATA[J Psychopharmacol]]></source>
<year>2003</year>
<volume>17</volume>
<page-range>342-5</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>72</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morgan]]></surname>
<given-names><![CDATA[M.J.]]></given-names>
</name>
<name>
<surname><![CDATA[McFie]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Fleetwood]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?.]]></article-title>
<source><![CDATA[Psychopharmacology (Berl)]]></source>
<year>2002</year>
<volume>159</volume>
<page-range>294-303</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>73</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greer]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Strassman]]></surname>
<given-names><![CDATA[R.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Information on &#8220;Ecstasy&#8221;.]]></article-title>
<source><![CDATA[Am J Psychiatry]]></source>
<year>1985</year>
<volume>142</volume>
<page-range>1391</page-range></nlm-citation>
</ref>
<ref id="B74">
<label>74</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCann]]></surname>
<given-names><![CDATA[U.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Ricaurte]]></surname>
<given-names><![CDATA[G.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lasting neuropsychiatric sequelae of (+&#8722;)methylenedioxymethamphetamine (&#8220;ecstasy&#8221;) in recreational users.]]></article-title>
<source><![CDATA[J Clin Psychopharmacol]]></source>
<year>1991</year>
<volume>11</volume>
<page-range>302-5</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>75</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Whitaker-Azmitia]]></surname>
<given-names><![CDATA[P.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Aronson]]></surname>
<given-names><![CDATA[T.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Ecstasy&#8221; (MDMA)-induced panic]]></article-title>
<source><![CDATA[Am J Psychiatry]]></source>
<year>1989</year>
<volume>146</volume>
<page-range>119</page-range></nlm-citation>
</ref>
<ref id="B76">
<label>76</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Creighton]]></surname>
<given-names><![CDATA[F.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Black]]></surname>
<given-names><![CDATA[D.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Hyde]]></surname>
<given-names><![CDATA[C.E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Ecstasy&#8221; psychosis and flashbacks.]]></article-title>
<source><![CDATA[Br J Psychiatry]]></source>
<year>1991</year>
<volume>159</volume>
<page-range>713-5</page-range></nlm-citation>
</ref>
<ref id="B77">
<label>77</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peroutka]]></surname>
<given-names><![CDATA[S.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Newman]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users.]]></article-title>
<source><![CDATA[Neuropsychopharmacology]]></source>
<year>1988</year>
<volume>1</volume>
<page-range>273-7</page-range></nlm-citation>
</ref>
<ref id="B78">
<label>78</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCann]]></surname>
<given-names><![CDATA[U.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Ricaurte]]></surname>
<given-names><![CDATA[G.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MDMA (&#8220;ecstasy&#8221;) and panic disorder: induction by a single dose]]></article-title>
<source><![CDATA[Biol Psychiatry]]></source>
<year>1992</year>
<volume>32</volume>
<page-range>950-953.</page-range></nlm-citation>
</ref>
<ref id="B79">
<label>79</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pallanti]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Mazzi]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MDMA (Ecstasy) precipitation of panic disorder.]]></article-title>
<source><![CDATA[Biol Psychiatry]]></source>
<year>1992</year>
<volume>32</volume>
<page-range>91-5</page-range></nlm-citation>
</ref>
<ref id="B80">
<label>80</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quednow]]></surname>
<given-names><![CDATA[B.B.]]></given-names>
</name>
<name>
<surname><![CDATA[Jessen]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Kuhn]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Maier]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Daum]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Memory deficits in abstinent MDMA (Ecstasy) users: neuropsychological evidence of frontal dysfunction]]></article-title>
<source><![CDATA[J Psychopharmacol]]></source>
<year>2006</year>
<volume>20</volume>
<page-range>373-84</page-range></nlm-citation>
</ref>
<ref id="B81">
<label>81</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gouzoulis-Mayfrank]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Thimm]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Rezk]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Hensen]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Daumann]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users.]]></article-title>
<source><![CDATA[Prog Neuropsychopharmacol Biol Psychiatry]]></source>
<year>2003</year>
<volume>27</volume>
<page-range>819-27</page-range></nlm-citation>
</ref>
<ref id="B82">
<label>82</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[H.C.]]></given-names>
</name>
<name>
<surname><![CDATA[McLean]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[J.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Parrott]]></surname>
<given-names><![CDATA[A.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Sahakian]]></surname>
<given-names><![CDATA[B.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA (&#8220;ecstasy&#8221;) polydrug users.]]></article-title>
<source><![CDATA[Psychopharmacology]]></source>
<year>2002</year>
<volume>162</volume>
<page-range>203-14</page-range></nlm-citation>
</ref>
<ref id="B83">
<label>83</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parrott]]></surname>
<given-names><![CDATA[A.C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity.]]></article-title>
<source><![CDATA[Pharmacol Biochem Behav]]></source>
<year>2002</year>
<volume>71</volume>
<page-range>837-44</page-range></nlm-citation>
</ref>
<ref id="B84">
<label>84</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ben-Abraham]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Szold]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Rudick]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Weinbroum]]></surname>
<given-names><![CDATA[A.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8216;Ecstasy&#8217; intoxication: life-threatening manifestations and resuscitative measures in the intensive care setting]]></article-title>
<source><![CDATA[Eur J Emerg Med]]></source>
<year>2003</year>
<volume>10:</volume>
<page-range>309-13</page-range></nlm-citation>
</ref>
<ref id="B85">
<label>85</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gussow]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tox rounds: ecstasy: a dangerous &#8216;party&#8217; drug]]></article-title>
<source><![CDATA[Emerg Med News]]></source>
<year>2010</year>
<volume>32</volume>
</nlm-citation>
</ref>
<ref id="B86">
<label>86</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[A. Thakkar]]></surname>
<given-names><![CDATA[K. Parekh]]></given-names>
</name>
<name>
<surname><![CDATA[K. El Hachem]]></surname>
<given-names><![CDATA[E. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mohanraj, "A Case of MDMA-Associated Cerebral and Pulmonary Edema Requiring ECMO",]]></article-title>
<source><![CDATA[Case Reports in Critical Care]]></source>
<year>2017</year>
<page-range>4</page-range></nlm-citation>
</ref>
<ref id="B87">
<label>87</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[A.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute toxic effects of &#8216;ecstasy&#8217; (MDMA) and related compounds: overview of pathophysiology and clinical management]]></article-title>
<source><![CDATA[Br J Anaesth]]></source>
<year>2006</year>
<volume>96</volume>
<page-range>678-85</page-range></nlm-citation>
</ref>
<ref id="B88">
<label>88</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Armenian P.]]></surname>
<given-names><![CDATA[Mamantov T.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Olson K.R.]]></surname>
<given-names><![CDATA[et. al.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple MDMA (ecstasy) overdoses at a rave event: a case series.]]></article-title>
<source><![CDATA[J Intensive Care Med]]></source>
<year>2013</year>
<volume>28</volume>
<page-range>252-8</page-range></nlm-citation>
</ref>
<ref id="B89">
<label>89.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walubo]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Seger]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fatal multi-organ failure after suicidal overdose with MDMA, &#8216;ecstasy&#8217;: case report and review of the literature.]]></article-title>
<source><![CDATA[Hum Exp Toxicol]]></source>
<year>1999</year>
<volume>18</volume>
<page-range>119-25</page-range></nlm-citation>
</ref>
<ref id="B90">
<label>90</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simpson]]></surname>
<given-names><![CDATA[D.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Rumack]]></surname>
<given-names><![CDATA[B.H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Methylenedioxyamphetamine: clinical description of overdose, death, and review of pharmacology]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>1981</year>
<volume>141</volume>
<page-range>1507-9</page-range></nlm-citation>
</ref>
<ref id="B91">
<label>91</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haaland]]></surname>
<given-names><![CDATA[Astrid]]></given-names>
</name>
<name>
<surname><![CDATA[Warman]]></surname>
<given-names><![CDATA[Elliot]]></given-names>
</name>
<name>
<surname><![CDATA[Pushkar]]></surname>
<given-names><![CDATA[Illya]]></given-names>
</name>
<name>
<surname><![CDATA[Likourezos]]></surname>
<given-names><![CDATA[Antonios]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Isolated non-cardiogenic pulmonary edema- A rare complication of MDMA toxicity.]]></article-title>
<source><![CDATA[Am. J. Emerg. Med]]></source>
<year>2017</year>
<volume>35</volume>
<page-range>1385-6</page-range></nlm-citation>
</ref>
<ref id="B92">
<label>92</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[S.H]]></given-names>
</name>
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[T.I]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[W.J]]></given-names>
</name>
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[C.C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MDMA-induced acute pulmonary edema in a patient without other organ dysfunction.]]></article-title>
<source><![CDATA[Am J Emerg Med]]></source>
<year>2006</year>
<page-range>734-6</page-range></nlm-citation>
</ref>
<ref id="B93">
<label>93</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haaland]]></surname>
<given-names><![CDATA[Astrid]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Isolated non-cardiogenic pulmonary edema-a rare complication of MDMA toxicity."]]></article-title>
<source><![CDATA[The American journal of emergency medicine.]]></source>
<year>2017</year>
<page-range>1385-e3</page-range></nlm-citation>
</ref>
<ref id="B94">
<label>94</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maharaj R.]]></surname>
<given-names><![CDATA[Pingitore A.]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MDMA-induced acute liver failure and transient abdominal pneumatosis.]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2015</year>
<volume>110</volume>
<page-range>963</page-range></nlm-citation>
</ref>
<ref id="B95">
<label>95.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goorney]]></surname>
<given-names><![CDATA[B.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Scholes]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transient haemolytic anaemia due to ecstasy in a patient on HAART]]></article-title>
<source><![CDATA[Int J STD AIDS]]></source>
<year>2002</year>
<volume>13</volume>
<page-range>651</page-range></nlm-citation>
</ref>
<ref id="B96">
<label>96</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Banerjee]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Bong]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pneumomediastinum in association with MDMA ingestion]]></article-title>
<source><![CDATA[J Emerg Med]]></source>
<year>2001</year>
<volume>20:</volume>
<page-range>305-6</page-range></nlm-citation>
</ref>
<ref id="B97">
<label>97</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stull]]></surname>
<given-names><![CDATA[B.W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Spontaneous pneumomediastinum following ecstasy ingestion and sexual intercourse.]]></article-title>
<source><![CDATA[Emerg Med J]]></source>
<year>2008</year>
<volume>25</volume>
<page-range>113-4</page-range></nlm-citation>
</ref>
<ref id="B98">
<label>98</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[C.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Chau]]></surname>
<given-names><![CDATA[L.F.]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[C.H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Massive spontaneous haemopneumothorax and ecstasy abuse]]></article-title>
<source><![CDATA[Hong Kong J Emerg Med]]></source>
<year>2004</year>
<volume>11</volume>
<page-range>94-7</page-range></nlm-citation>
</ref>
<ref id="B99">
<label>99</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villanueva Cañadas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pla Martínez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Capítulo 50, Introducción a la Toxicología. Gisbert Calabuig. Medicina Legal y Toxicología]]></source>
<year>2019</year>
<edition>Séptima</edition>
<page-range>773-8</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[El Sevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B100">
<label>100</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pacifici]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Zuccaro]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Farre]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Pichini]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Di Carlo]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Roset]]></surname>
<given-names><![CDATA[P.N.]]></given-names>
</name>
<name>
<surname><![CDATA[Palmi]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ortuno]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Menoyo]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Segura]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[de la Torre]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus noncontrolled settings]]></article-title>
<source><![CDATA[Ann NY Acad Sci]]></source>
<year>2002</year>
<volume>965</volume>
<page-range>421-33</page-range></nlm-citation>
</ref>
<ref id="B101">
<label>101</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palamar]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kamboukos]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An examination of sociodemographic correlates of ecstasy use among high school seniors in the United States]]></article-title>
<source><![CDATA[Subst Use Misuse]]></source>
<year>2014</year>
<volume>49</volume>
<page-range>1774</page-range></nlm-citation>
</ref>
<ref id="B102">
<label>102</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boyer]]></surname>
<given-names><![CDATA[EW]]></given-names>
</name>
<name>
<surname><![CDATA[Shannon]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The serotonin syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2005</year>
<volume>352</volume>
<page-range>1112</page-range></nlm-citation>
</ref>
<ref id="B103">
<label>103</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Birmes]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Coppin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Schmitt]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lauque]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serotonin syndrome: a brief review]]></article-title>
<source><![CDATA[CMAJ]]></source>
<year>2003</year>
<volume>168</volume>
<page-range>1439</page-range></nlm-citation>
</ref>
<ref id="B104">
<label>104</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mason]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Balcezak]]></surname>
<given-names><![CDATA[TJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serotonin syndrome. Presentation of 2 cases and review of the literature]]></article-title>
<source><![CDATA[Medicine (Baltimore)]]></source>
<year>2000</year>
<volume>79</volume>
<page-range>201</page-range></nlm-citation>
</ref>
<ref id="B105">
<label>105</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bodner]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Lynch]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kahn]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serotonin syndrome]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>1995</year>
<volume>45</volume>
</nlm-citation>
</ref>
<ref id="B106">
<label>106</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mills]]></surname>
<given-names><![CDATA[KC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serotonin syndrome. A clinical update.]]></article-title>
<source><![CDATA[Crit Care Clin]]></source>
<year>1997</year>
<volume>13</volume>
<page-range>763</page-range></nlm-citation>
</ref>
<ref id="B107">
<label>107</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Edward]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Boyer]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<source><![CDATA[Síndrome serotoninérgico (Toxicidad serotoninérgica).]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B108">
<label>108</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Nouri]]></surname>
<given-names><![CDATA[ZL]]></given-names>
</name>
<name>
<surname><![CDATA[Reese]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Terrell]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug-induced thrombotic microangiopathy: a systematic review of published reports.]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2015</year>
<volume>125</volume>
<page-range>616</page-range></nlm-citation>
</ref>
<ref id="B109">
<label>109</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reese]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Bougie]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Curtis]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug-induced thrombotic microangiopathy: Experience of the Oklahoma Registry and the BloodCenter of Wisconsin]]></article-title>
<source><![CDATA[Am J Hematol]]></source>
<year>2015</year>
<volume>90</volume>
<page-range>406</page-range></nlm-citation>
</ref>
<ref id="B110">
<label>110</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[James N]]></surname>
<given-names><![CDATA[George]]></given-names>
</name>
<name>
<surname><![CDATA[Adam Cuker]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<source><![CDATA[Microangiopatía inducidad por drogas. Base de datos Up to Date, publicación con revisión de literatura hasta julio del 2021]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B111">
<label>111.</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaasch]]></surname>
<given-names><![CDATA[William H]]></given-names>
</name>
</person-group>
<source><![CDATA[Valvular heart disease induced by drugs]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B112">
<label>112</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pellikka]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Tajik]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Khandheria]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1993</year>
<volume>87</volume>
<page-range>1188</page-range></nlm-citation>
</ref>
<ref id="B113">
<label>113</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robiolio]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Rigolin]]></surname>
<given-names><![CDATA[VH]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1995</year>
<volume>92</volume>
<page-range>790</page-range></nlm-citation>
</ref>
<ref id="B114">
<label>114</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Setola]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Hufeisen]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Grande-Allen]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.]]></article-title>
<source><![CDATA[Mol Pharmacol]]></source>
<year>2003</year>
<volume>63</volume>
<page-range>1223</page-range></nlm-citation>
</ref>
<ref id="B115">
<label>115</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rohrig]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Prouty]]></surname>
<given-names><![CDATA[RW.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tissue distribution of methylenedioxymethamphetamine]]></article-title>
<source><![CDATA[J Anal Toxicol]]></source>
<year>1992</year>
<volume>16</volume>
<page-range>52-3</page-range></nlm-citation>
</ref>
<ref id="B116">
<label>116.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Mozayani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fierro]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Poklis]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Distribution of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) stereoisomers in a fatal poisoning]]></article-title>
<source><![CDATA[Forensic Sci Int]]></source>
<year>1996</year>
<volume>83</volume>
<page-range>111-9</page-range></nlm-citation>
</ref>
<ref id="B117">
<label>117</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalant]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The pharmacology and toxicology of &#8220;ecstacy&#8221; (MDMA) and related drugs.]]></article-title>
<source><![CDATA[CMAJ]]></source>
<year>2001</year>
<volume>165</volume>
<page-range>917-28</page-range></nlm-citation>
</ref>
<ref id="B118">
<label>118</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Theune]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Esser]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Druschky]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
<name>
<surname><![CDATA[Interschick]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Patscheke]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Grand-mal-Serie nach Ecstasy-Einnahme.]]></article-title>
<source><![CDATA[Nervenarzt]]></source>
<year>1999</year>
<volume>70</volume>
<page-range>1094-7.</page-range></nlm-citation>
</ref>
<ref id="B119">
<label>119</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spoelder]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Louwerens]]></surname>
<given-names><![CDATA[JKG]]></given-names>
</name>
<name>
<surname><![CDATA[Krens]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Unexpected Serotonin Syndrome, Epileptic Seizures, and Cerebral Edema Following 2,5-dimethoxy-4-bromophenethylamine Ingestion]]></article-title>
<source><![CDATA[J Forensic Sci]]></source>
<year>2019</year>
<volume>64:</volume>
<page-range>1950-2</page-range></nlm-citation>
</ref>
<ref id="B120">
<label>120</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thornton]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Hoehn]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gerona]]></surname>
<given-names><![CDATA[RR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seizures, Systemic Inflammatory Response, and Rhabdomyolysis Associated With Laboratory-Confirmed 2C-I and 25-I Exposure]]></article-title>
<source><![CDATA[Pediatr Emerg Care]]></source>
<year>2018</year>
<volume>34</volume>
<page-range>1-3.</page-range></nlm-citation>
</ref>
<ref id="B121">
<label>121</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palamar]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Salomone]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vincenti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cleland]]></surname>
<given-names><![CDATA[CM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Detection of "bath salts" and other novel psychoactive substances in hair samples of ecstasy/MDMA/"Molly" users]]></article-title>
<source><![CDATA[Drug Alcohol Depend]]></source>
<year>2016</year>
<volume>161</volume>
<page-range>200</page-range></nlm-citation>
</ref>
<ref id="B122">
<label>122</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Byard]]></surname>
<given-names><![CDATA[R.W.]]></given-names>
</name>
<name>
<surname><![CDATA[Gilbert]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Lokan]]></surname>
<given-names><![CDATA[R.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Amphetamine derivative fatalities in South Australia-is &#8220;Ecstasy&#8221; the culprit?.]]></article-title>
<source><![CDATA[Am J Forensic Med Pathol]]></source>
<year>1998</year>
<volume>19</volume>
<page-range>261-5</page-range></nlm-citation>
</ref>
<ref id="B123">
<label>123</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carter]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Rutty]]></surname>
<given-names><![CDATA[GN]]></given-names>
</name>
<name>
<surname><![CDATA[Milroy]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Forrest]]></surname>
<given-names><![CDATA[AR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Deaths associated with MBDB use]]></article-title>
<source><![CDATA[Int J Legal Med]]></source>
<year>2000</year>
<volume>113</volume>
<page-range>168-70</page-range></nlm-citation>
</ref>
<ref id="B124">
<label>124.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Milroy]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Forrest]]></surname>
<given-names><![CDATA[ARW.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathology of deaths associated with &#8220;ecstasy&#8221; and &#8220;eve&#8221; misuse]]></article-title>
<source><![CDATA[J Clin Pathol]]></source>
<year>1996</year>
<volume>49</volume>
<page-range>149-53</page-range></nlm-citation>
</ref>
<ref id="B125">
<label>125</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sondermann]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kovar]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Screening experiments of ecstasy street samples using near infrared spectroscopy]]></article-title>
<source><![CDATA[Forensic Sci Int]]></source>
<year>1999</year>
<volume>106</volume>
</nlm-citation>
</ref>
<ref id="B126">
<label>126.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christopherson]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Amphetamine designer drugs - an overview and epidemiology.]]></article-title>
<source><![CDATA[Toxicol Lett]]></source>
<year>2000</year>
</nlm-citation>
</ref>
<ref id="B127">
<label>127</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parrott]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Lasky]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ecstasy (MDMA) effects upon mood and cognition before, during, and after a Saturday night dance.]]></article-title>
<source><![CDATA[Psychopharmacology]]></source>
<year>1998</year>
<volume>139</volume>
<page-range>261-8</page-range></nlm-citation>
</ref>
<ref id="B128">
<label>128</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dar]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[McBrien]]></surname>
<given-names><![CDATA[ME.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MDMA induced hyperthermia: report of a fatality and review of current therapy.]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>1996</year>
<volume>22</volume>
<page-range>995-6</page-range></nlm-citation>
</ref>
<ref id="B129">
<label>129</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walubo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Seger]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fatal multi-organ failure after suicidal overdose with MDMA, &#8216;ecstasy&#8217;: case report and review of the literature]]></article-title>
<source><![CDATA[Hum Exp Toxicol]]></source>
<year>1999</year>
<volume>18</volume>
<page-range>119-25</page-range></nlm-citation>
</ref>
<ref id="B130">
<label>130.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weinmann]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Bohnert]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lethal monointoxication by overdosage of MDEA]]></article-title>
<source><![CDATA[Forensic Sci Int]]></source>
<year>1998</year>
<volume>91</volume>
<page-range>91-101</page-range></nlm-citation>
</ref>
<ref id="B131">
<label>131</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harries]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[De Silva]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ecstasy&#8217; and intracerebral haemorrhage]]></article-title>
<source><![CDATA[Scott Med J]]></source>
<year>1992</year>
</nlm-citation>
</ref>
<ref id="B132">
<label>132.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Green A.R.]]></surname>
<given-names><![CDATA[Mechan A.O.]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott J.M.]]></surname>
<given-names><![CDATA[et. al.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, &#8220;ecstasy&#8217;&#8221;).]]></article-title>
<source><![CDATA[Pharmacol Rev]]></source>
<year>2003</year>
<volume>55:</volume>
<page-range>463-508</page-range></nlm-citation>
</ref>
<ref id="B133">
<label>133</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Farré]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[de la Torre]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Roset]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
<name>
<surname><![CDATA[Ortuño]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Segura]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylene-dioxymethamphetamine in humans]]></article-title>
<source><![CDATA[J Pharmacol Exp Ther]]></source>
<year>1999</year>
<volume>290</volume>
<page-range>136-45</page-range></nlm-citation>
</ref>
<ref id="B134">
<label>134</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verebey]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Alrazi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jaffe]]></surname>
<given-names><![CDATA[JH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The complications of &#8216;ecstasy&#8217; (MDMA).]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1988</year>
<volume>259</volume>
<page-range>1649-50</page-range></nlm-citation>
</ref>
<ref id="B135">
<label>135</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Farre]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[de la Torre]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.]]></article-title>
<source><![CDATA[J Pharmacol Exp Ther]]></source>
<year>1999</year>
<volume>290</volume>
<page-range>136-45</page-range></nlm-citation>
</ref>
<ref id="B136">
<label>136</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Otton]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Inaba]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kalow]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Sellers]]></surname>
<given-names><![CDATA[EM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interactions of amphetamine analogs with human liver CYP2D6]]></article-title>
<source><![CDATA[Biochem Pharmacol]]></source>
<year>1997</year>
<volume>53</volume>
<page-range>1605-12</page-range></nlm-citation>
</ref>
<ref id="B137">
<label>137</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tucker]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
<name>
<surname><![CDATA[Lennard]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Ellis]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6).]]></article-title>
<source><![CDATA[Biochem Pharmacol]]></source>
<year>1994</year>
<volume>47</volume>
<page-range>1151-6</page-range></nlm-citation>
</ref>
<ref id="B138">
<label>138</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kreth]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kovar]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Schwab]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of the human cytochromes P450 involved in the oxidative metabolism of "ecstasy"-related designer drugs]]></article-title>
<source><![CDATA[Biochem Pharmacol]]></source>
<year>2000</year>
<volume>59</volume>
<page-range>1563-71</page-range></nlm-citation>
</ref>
<ref id="B139">
<label>139</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de la Torre]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Farre]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ortuno]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-linear pharmacokinetics of MDMA ('ecstasy') in humans.]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>2000</year>
<volume>49</volume>
<page-range>104-9</page-range></nlm-citation>
</ref>
<ref id="B140">
<label>140</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Bickeboeller-Friedrich]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kraemer]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[FT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs (&#8216;ecstasy&#8217;).]]></article-title>
<source><![CDATA[Toxicol Lett]]></source>
<year>2000</year>
</nlm-citation>
</ref>
<ref id="B141">
<label>141</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de la Torre]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Farre]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Roset]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition.]]></article-title>
<source><![CDATA[Ther Drug Monit]]></source>
<year>2004</year>
<volume>26</volume>
<page-range>137-44</page-range></nlm-citation>
</ref>
<ref id="B142">
<label>142.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colado]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[AR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.]]></article-title>
<source><![CDATA[Br J Pharmacol]]></source>
<year>1995</year>
<volume>115</volume>
<page-range>1281-9</page-range></nlm-citation>
</ref>
<ref id="B143">
<label>143</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shimada]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yamazaki]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mimura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians]]></article-title>
<source><![CDATA[Pharmacol Exp Ther]]></source>
<year>1994</year>
<volume>270</volume>
<page-range>414-23</page-range></nlm-citation>
</ref>
<ref id="B144">
<label>144.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yeo]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Rostami-Hodjegan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tucker]]></surname>
<given-names><![CDATA[GT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abundance of cytochrome P450 in human liver: a meta-analysis]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>2003</year>
<volume>57</volume>
<page-range>687-8</page-range></nlm-citation>
</ref>
<ref id="B145">
<label>145.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ingelman-Sundberg]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[WE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Unravelling the functional genomics of the human CYP2D6 gene locus]]></article-title>
<source><![CDATA[Pharmacogenetics]]></source>
<year>2001</year>
<volume>11</volume>
<page-range>553-4</page-range></nlm-citation>
</ref>
<ref id="B146">
<label>146.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O&#8217;Mathuna]]></surname>
<given-names><![CDATA[Brian]]></given-names>
</name>
<name>
<surname><![CDATA[Magi.]]></surname>
<given-names><![CDATA[Farre]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Consequences of 3,4-Methylenedioxymethamphetamine Induced CYP2D6 Inhibition in Humans .]]></article-title>
<source><![CDATA[Journal of Clinical Psycopharmacology]]></source>
<year>2008</year>
<volume>28</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>523-9</page-range></nlm-citation>
</ref>
<ref id="B147">
<label>147</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zanger]]></surname>
<given-names><![CDATA[UM]]></given-names>
</name>
<name>
<surname><![CDATA[Raimundo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Eichelbaum]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry]]></article-title>
<source><![CDATA[Naunyn Schmiedebergs Arch Pharmacol]]></source>
<year>2004</year>
<volume>369</volume>
</nlm-citation>
</ref>
<ref id="B148">
<label>148</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lovlie]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Daly]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Matre]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?]]></article-title>
<source><![CDATA[Pharmacogenetics]]></source>
<year>2001</year>
<volume>11</volume>
<page-range>45-55</page-range></nlm-citation>
</ref>
<ref id="B149">
<label>149</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bogni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Monshouwer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Moscone]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles.]]></article-title>
<source><![CDATA[Toxicol In Vitro]]></source>
<year>2005</year>
<volume>19</volume>
<page-range>621-9</page-range></nlm-citation>
</ref>
<ref id="B150">
<label>150.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Farre]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[de la Torre]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mathuna]]></surname>
<given-names><![CDATA[BO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics.]]></article-title>
<source><![CDATA[Psychopharmacology (Berl).]]></source>
<year>2004</year>
<volume>173</volume>
<page-range>364-75</page-range></nlm-citation>
</ref>
<ref id="B151">
<label>151</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liston]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[DeVane]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Boulton]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers]]></article-title>
<source><![CDATA[J Clin Psychopharmacol]]></source>
<year>2002</year>
<volume>22</volume>
<page-range>169-173.</page-range></nlm-citation>
</ref>
<ref id="B152">
<label>152</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Venkatakrishnan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Obach]]></surname>
<given-names><![CDATA[RS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude.]]></article-title>
<source><![CDATA[Drug Metab Dispos.]]></source>
<year>2005</year>
<volume>33</volume>
<page-range>845-52</page-range></nlm-citation>
</ref>
<ref id="B153">
<label>153</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jamei]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Heydari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA]]></article-title>
<source><![CDATA[J Psychopharmacol]]></source>
<year>2006</year>
<volume>20</volume>
<page-range>842-9</page-range></nlm-citation>
</ref>
<ref id="B154">
<label>154.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mueller]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[FT]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses]]></article-title>
<source><![CDATA[J Pharmacol Exp Ther.]]></source>
<year></year>
<volume>327</volume>
<page-range>38-44.</page-range></nlm-citation>
</ref>
<ref id="B155">
<label>155</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rudnick]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Wall]]></surname>
<given-names><![CDATA[SC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release.]]></article-title>
<source><![CDATA[Proc Natl Acad Sci U S A]]></source>
<year>1992</year>
<volume>89</volume>
<page-range>1817-21</page-range></nlm-citation>
</ref>
<ref id="B156">
<label>156</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rothman]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Baumann]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Dersch]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.]]></article-title>
<source><![CDATA[Synapse]]></source>
<year>2001</year>
<volume>39</volume>
<page-range>32-41</page-range></nlm-citation>
</ref>
<ref id="B157">
<label>157</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verrico]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Madras]]></surname>
<given-names><![CDATA[BK.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MDMA (ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment]]></article-title>
<source><![CDATA[Psychopharmacology]]></source>
<year>2007</year>
<volume>189</volume>
<page-range>489-503</page-range></nlm-citation>
</ref>
<ref id="B158">
<label>158</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rochester]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Kirchner]]></surname>
<given-names><![CDATA[JT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ecstasy (3,4-methylenedioxymethamphetamine): history, neurochemistry, and toxicology.]]></article-title>
<source><![CDATA[J Am Board Fam Pract]]></source>
<year>1999</year>
<volume>12</volume>
</nlm-citation>
</ref>
<ref id="B159">
<label>159</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shannon]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Methylenedioxymethamphetamine (MDMA, "Ecstasy").]]></article-title>
<source><![CDATA[Pediatr Emerg Care]]></source>
<year>2000</year>
<volume>16</volume>
<page-range>377</page-range></nlm-citation>
</ref>
<ref id="B160">
<label>160</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liechti]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Baumann]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gamma]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") are attenuated by the serotonin uptake inhibitor citalopram]]></article-title>
<source><![CDATA[Neuropsychopharmacology]]></source>
<year></year>
<volume>22</volume>
<page-range>513-21</page-range></nlm-citation>
</ref>
<ref id="B161">
<label>161.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simmler]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
<name>
<surname><![CDATA[Hysek]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Liechti]]></surname>
<given-names><![CDATA[ME.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects.]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2011</year>
<volume>96:</volume>
<page-range>2844-50</page-range></nlm-citation>
</ref>
<ref id="B162">
<label>162</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hysek]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Simmler]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
<name>
<surname><![CDATA[Nicola]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2012</year>
<volume>7</volume>
</nlm-citation>
</ref>
<ref id="B163">
<label>163</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hysek]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Brugger]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Simmler]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of the [alpha]2-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers.]]></article-title>
<source><![CDATA[J Pharmacol Exp Ther]]></source>
<year>2012</year>
<volume>340</volume>
<page-range>286-94</page-range></nlm-citation>
</ref>
<ref id="B164">
<label>164.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hysek]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Domes]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Liechti]]></surname>
<given-names><![CDATA[ME.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MDMA enhances "mind reading" of positive emotions and impairs "mind reading" of negative emotions]]></article-title>
<source><![CDATA[Psychopharmacology]]></source>
<year>2012</year>
<volume>222</volume>
<page-range>293-302</page-range></nlm-citation>
</ref>
<ref id="B165">
<label>165</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schenk]]></surname>
<given-names><![CDATA[Susan]]></given-names>
</name>
<name>
<surname><![CDATA[Newcombe]]></surname>
<given-names><![CDATA[David]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metilendioximetanfetamina (MDMA) en Psiquiatría: Pros, contras y sugerencias.]]></article-title>
<source><![CDATA[J Clin Pharmacol]]></source>
<year>2018</year>
<volume>38</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>632-8</page-range></nlm-citation>
</ref>
<ref id="B166">
<label>166</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Battaglia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Brooks]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
<name>
<surname><![CDATA[Kulsakdinun]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites]]></article-title>
<source><![CDATA[Eur J Pharmacol]]></source>
<year>1988</year>
<volume>149</volume>
<page-range>159-63</page-range></nlm-citation>
</ref>
<ref id="B167">
<label>167</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Cross]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Goodwin]]></surname>
<given-names><![CDATA[GM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy").]]></article-title>
<source><![CDATA[Psychopharmacology]]></source>
<year>1995</year>
<volume>119</volume>
<page-range>247-60</page-range></nlm-citation>
</ref>
<ref id="B168">
<label>168</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Obradovic]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Imel]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system]]></article-title>
<source><![CDATA[Prog Neurobiol.]]></source>
<year>1996</year>
<volume>49</volume>
<page-range>455-79</page-range></nlm-citation>
</ref>
<ref id="B169">
<label>169</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hysek]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Simmler]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
<name>
<surname><![CDATA[Ineichen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans]]></article-title>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>2011</year>
<volume>90</volume>
<page-range>246-55</page-range></nlm-citation>
</ref>
<ref id="B170">
<label>170</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Callaway]]></surname>
<given-names><![CDATA[C.W.]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[M.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Gold]]></surname>
<given-names><![CDATA[L.H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Amphetamine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists]]></article-title>
<source><![CDATA[Psychopharmacology]]></source>
<year>1991</year>
<volume>104</volume>
</nlm-citation>
</ref>
<ref id="B171">
<label>171</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sarkar]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Schmued]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurotoxicity of ecstasy (MDMA): an overview]]></article-title>
<source><![CDATA[Curr Pharm Biotechnol]]></source>
<year>2010</year>
<volume>11</volume>
<page-range>460-9</page-range></nlm-citation>
</ref>
<ref id="B172">
<label>172</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carhart-Harris]]></surname>
<given-names><![CDATA[R. L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effects of acutely administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting state func-tional connectivity]]></article-title>
<source><![CDATA[Biol. Psychiatry]]></source>
<year>2015</year>
<volume>78</volume>
<page-range>554-62</page-range></nlm-citation>
</ref>
<ref id="B173">
<label>173</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kamilar-Britt]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Bedi]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): controlled studies in humans and laboratory animals.]]></article-title>
<source><![CDATA[Neurosci. Biobehav. Rev]]></source>
<year>2015</year>
<volume>57</volume>
<page-range>433-46</page-range></nlm-citation>
</ref>
<ref id="B174">
<label>174</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walpola]]></surname>
<given-names><![CDATA[I. C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Altered insula connectivity under MDMA.]]></article-title>
<source><![CDATA[Neuropsychopharmacology]]></source>
<year>2017</year>
<volume>42</volume>
<page-range>2152-62</page-range></nlm-citation>
</ref>
<ref id="B175">
<label>175</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bedi]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Phan]]></surname>
<given-names><![CDATA[K. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Angstadt]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[de Wit]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of MDMA on sociability and neural response to social threat and social reward.]]></article-title>
<source><![CDATA[Psychopharmacology]]></source>
<year>2009</year>
<volume>207</volume>
<page-range>73-83</page-range></nlm-citation>
</ref>
<ref id="B176">
<label>176</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sofuoglu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Poling]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atomoxetine attenuates dextroamphetamine effects in humans]]></article-title>
<source><![CDATA[Am J Drug Alcohol Abuse]]></source>
<year>2009</year>
<volume>35</volume>
<page-range>412-6</page-range></nlm-citation>
</ref>
<ref id="B177">
<label>177.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Newton]]></surname>
<given-names><![CDATA[TF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A perhaps unexpected role of norepinephrine in actions of MDMA]]></article-title>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>2011</year>
<volume>90</volume>
<page-range>215-6</page-range></nlm-citation>
</ref>
<ref id="B178">
<label>178</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Newton]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[2nd]]></surname>
<given-names><![CDATA[De La Garza R]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Noradrenergic a1 receptor antagonist treatment attenuates positive subjec-tive effects of cocaine in humans: a randomized trial]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2012</year>
<volume>7</volume>
</nlm-citation>
</ref>
<ref id="B179">
<label>179</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Selken]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nichols]]></surname>
<given-names><![CDATA[DE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[alpha1-Adrenergic receptors mediate the locomotor response to systemic administration of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) in rats.]]></article-title>
<source><![CDATA[Pharmacol Biochem Behav]]></source>
<year>2007</year>
<volume>86</volume>
<page-range>622-30</page-range></nlm-citation>
</ref>
<ref id="B180">
<label>180</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wellman]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cepeda-Benito]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cocaine-induced hypophagia and hyperlocomotion in rats are attenuated by prazosin.]]></article-title>
<source><![CDATA[Eur J Pharmacol]]></source>
<year>2002</year>
<volume>455</volume>
<page-range>117-26</page-range></nlm-citation>
</ref>
<ref id="B181">
<label>181</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drouin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Darracq]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Trovero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[alpha1b-Adrenergic receptors control locomotor and rewarding effects of psychost-imulants and opiates]]></article-title>
<source><![CDATA[J Neurosci]]></source>
<year>2002</year>
<volume>22</volume>
<page-range>2873-84</page-range></nlm-citation>
</ref>
<ref id="B182">
<label>182</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vanderschuren]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Beemster]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Schoffelmeer]]></surname>
<given-names><![CDATA[AN.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[On the role of noradrenaline in psychostimulant-induced psychomotor activity and sensitization]]></article-title>
<source><![CDATA[Psychopharmacology]]></source>
<year>2003</year>
<volume>169</volume>
<page-range>176-85</page-range></nlm-citation>
</ref>
<ref id="B183">
<label>183</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Darracq]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Blanc]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Glowinski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of D-amphetamine.]]></article-title>
<source><![CDATA[J Neurosci]]></source>
<year>1998</year>
<volume>18</volume>
<page-range>2729-39</page-range></nlm-citation>
</ref>
<ref id="B184">
<label>184</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Auclair]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cotecchia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Glowinski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[D-Amphetamine fails to increase extracellular dopamine levels in mice lacking alpha 1b-adrenergic receptors: relationship between functional and nonfunctional dopamine release.]]></article-title>
<source><![CDATA[J Neurosci]]></source>
<year>2002</year>
<volume>22</volume>
<page-range>9150-4</page-range></nlm-citation>
</ref>
<ref id="B185">
<label>185</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Sung]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Fuh]]></surname>
<given-names><![CDATA[SM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Locally application of amphetamine into the ventral tegmental area enhances dopamine re-lease in the nucleus accumbens and the medial prefrontal cortex through noradrenergic neurotransmission.]]></article-title>
<source><![CDATA[J Pharmacol Exp Ther]]></source>
<year>1996</year>
<volume>278</volume>
<page-range>725-31</page-range></nlm-citation>
</ref>
<ref id="B186">
<label>186</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hysek]]></surname>
<given-names><![CDATA[Cedric]]></given-names>
</name>
<name>
<surname><![CDATA[Fink]]></surname>
<given-names><![CDATA[Anja]]></given-names>
</name>
<name>
<surname><![CDATA[Simmler]]></surname>
<given-names><![CDATA[Linda]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[1-Adrenergic Receptors Contribute to the Acute Effects of 3,4-Methylenedioxymethamphetamine in Humans.]]></article-title>
<source><![CDATA[J Clin Psychopharmacol.]]></source>
<year>2013</year>
<volume>33</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>658-66</page-range></nlm-citation>
</ref>
<ref id="B187">
<label>187</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[XY]]></given-names>
</name>
<name>
<surname><![CDATA[Kosten]]></surname>
<given-names><![CDATA[TA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prazosin, an a1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking.]]></article-title>
<source><![CDATA[Biol Psychiatry]]></source>
<year>2005</year>
<volume>57</volume>
<page-range>1202-4</page-range></nlm-citation>
</ref>
<ref id="B188">
<label>188</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haile]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Mahoney]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<given-names><![CDATA[Newton]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacotherapeutics directed at deficiencies associated with cocaine de-pendence: focus on dopamine, norepinephrine and glutamate]]></article-title>
<source><![CDATA[Pharmacol Ther]]></source>
<year>2012</year>
<volume>134</volume>
<page-range>260-77</page-range></nlm-citation>
</ref>
<ref id="B189">
<label>189</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McDaid]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Docherty]]></surname>
<given-names><![CDATA[JR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vascular actions of MDMA involve alpha1 and alpha2-adrenoceptors in the anaesthetized rat]]></article-title>
<source><![CDATA[Br J Pharmacol.]]></source>
<year>2001</year>
<volume>133</volume>
</nlm-citation>
</ref>
<ref id="B190">
<label>190</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Larios]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez-Viquez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of alpha adrenoceptors and nitric oxide on cardiovascular responses in acute and chronic hypertension]]></article-title>
<source><![CDATA[J Physiol Biochem.]]></source>
<year>2011</year>
<volume>67</volume>
<page-range>427-35</page-range></nlm-citation>
</ref>
<ref id="B191">
<label>191.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hysek]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Vollenweider]]></surname>
<given-names><![CDATA[FX]]></given-names>
</name>
<name>
<surname><![CDATA[Liechti]]></surname>
<given-names><![CDATA[ME.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of a [beta]-blocker on the cardiovascular response to MDMA (ecstasy).]]></article-title>
<source><![CDATA[Emerg Med J.]]></source>
<year>2010</year>
<volume>27</volume>
<page-range>586-9</page-range></nlm-citation>
</ref>
<ref id="B192">
<label>192</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hysek]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Schmid]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Rickli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in hu-mans.]]></article-title>
<source><![CDATA[Br J Pharmacol]]></source>
<year>2012</year>
<volume>166</volume>
<page-range>2777-288</page-range></nlm-citation>
</ref>
<ref id="B193">
<label>193</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lester]]></surname>
<given-names><![CDATA[S.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Baggott]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Welm]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Schiller]]></surname>
<given-names><![CDATA[N.B.]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[R.T.]]></given-names>
</name>
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Mendelson]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2000</year>
<volume>133</volume>
<page-range>969-73</page-range></nlm-citation>
</ref>
<ref id="B194">
<label>194</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schechter]]></surname>
<given-names><![CDATA[MD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MDMA as a discriminative stimulus: isomeric comparisons]]></article-title>
<source><![CDATA[Pharmacol Biochem Behav]]></source>
<year>1987</year>
<volume>27</volume>
<page-range>41-4</page-range></nlm-citation>
</ref>
<ref id="B195">
<label>195.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glennon]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dukat]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Initial characterization of PMMA as a discriminative stimulus.]]></article-title>
<source><![CDATA[Pharmacol Biochem Behav]]></source>
<year>1997</year>
<volume>57</volume>
<page-range>151-8</page-range></nlm-citation>
</ref>
<ref id="B196">
<label>196</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Letter]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Merchant]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hanson]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Gibb]]></surname>
<given-names><![CDATA[JW.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat]]></article-title>
<source><![CDATA[J Pharmacol Exp Ther]]></source>
<year>1988</year>
<volume>244</volume>
<page-range>977-82</page-range></nlm-citation>
</ref>
<ref id="B197">
<label>197</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[itzgerald]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Blanke]]></surname>
<given-names><![CDATA[RV]]></given-names>
</name>
<name>
<surname><![CDATA[Rosecrans]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Glennon]]></surname>
<given-names><![CDATA[RA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stereochemistry of the metabolism of MDMA to MDA]]></article-title>
<source><![CDATA[Life Sci]]></source>
<year>1989</year>
<volume>45</volume>
<page-range>295-301</page-range></nlm-citation>
</ref>
<ref id="B198">
<label>198</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eede H.V.]]></surname>
<given-names><![CDATA[et. al.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rhabdomyolysis in MDMA intoxication: a rapid and underestimated killer. &#8220;Clean&#8221; ecstasy, a safe party drug?.]]></article-title>
<source><![CDATA[J Emerg Med]]></source>
<year>2012</year>
<volume>42</volume>
<page-range>655-8</page-range></nlm-citation>
</ref>
<ref id="B199">
<label>199</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solowij]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recreational MDMA use in Sydney: a profile of &#8220;ecstacy&#8221; users and their experiences with the drug]]></article-title>
<source><![CDATA[Br J Addict]]></source>
<year>1992</year>
<volume>87</volume>
<page-range>1161-72</page-range></nlm-citation>
</ref>
<ref id="B200">
<label>200</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greene S.L.]]></surname>
<given-names><![CDATA[Dargan P.I.]]></given-names>
</name>
<name>
<surname><![CDATA[Kerins M.]]></surname>
<given-names><![CDATA[et. al.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple toxicity from 3,4-methylenedioxymethamphetamine (&#8220;ecstasy&#8221;).]]></article-title>
<source><![CDATA[Am J Emerg Med]]></source>
<year>2003</year>
<volume>21</volume>
<page-range>121-4</page-range></nlm-citation>
</ref>
<ref id="B201">
<label>201</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Regenthal]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Krüger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Preiss]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survival after massive &#8220;ecstasy&#8221; (MDMA) ingestion]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>1999</year>
<volume>25</volume>
<page-range>640-1</page-range></nlm-citation>
</ref>
<ref id="B202">
<label>202</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Libiseller]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Pavlic]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Grubwieser]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Rabl]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An announced suicide with ecstasy.]]></article-title>
<source><![CDATA[Int J Legal Med]]></source>
<year>2007</year>
<volume>121</volume>
<page-range>40-3</page-range></nlm-citation>
</ref>
<ref id="B203">
<label>203.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maldonado]]></surname>
<given-names><![CDATA[A. Luna]]></given-names>
</name>
<name>
<surname><![CDATA[Osuna Carrilo de Albornoz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Capítulo 74, Drogas de Abuso. Gisbert Calabuig. Medicina Legal y Toxicología.]]></source>
<year></year>
<edition>Séptima</edition>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[El Sevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B204">
<label>204</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernandez-Lopez]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Farre]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Roset]]></surname>
<given-names><![CDATA[P.N.]]></given-names>
</name>
<name>
<surname><![CDATA[Menoyo]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Pizarro]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Ortuno]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Torrens]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Cami]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[de la Torre]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective ef-fects, and pharmacokinetics.]]></article-title>
<source><![CDATA[J Pharmacol Exp Ther]]></source>
<year>2002</year>
<volume>300</volume>
<page-range>236-44</page-range></nlm-citation>
</ref>
<ref id="B205">
<label>205</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silins]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Copeland]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Dillon]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other sero-tonergic substances: hierarchy of risk.]]></article-title>
<source><![CDATA[Aust N Z J Psychiatry]]></source>
<year>2007</year>
<volume>41</volume>
<page-range>649-55</page-range></nlm-citation>
</ref>
<ref id="B206">
<label>206</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vuori]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ojanpera]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Nieminen]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Savolainen]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Wahlsten]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Jantti]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Death following ingestion of MDMA (ecstasy) and moclobemide]]></article-title>
<source><![CDATA[Addiction]]></source>
<year>2003</year>
<volume>98</volume>
<page-range>365-8</page-range></nlm-citation>
</ref>
<ref id="B207">
<label>207</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Granneman]]></surname>
<given-names><![CDATA[G.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Bertz]]></surname>
<given-names><![CDATA[R.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.]]></article-title>
<source><![CDATA[Clin Pharmacokinet]]></source>
<year>1998</year>
<volume>35</volume>
<page-range>275-91</page-range></nlm-citation>
</ref>
<ref id="B208">
<label>208.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCann]]></surname>
<given-names><![CDATA[UD]]></given-names>
</name>
<name>
<surname><![CDATA[Ridenour]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shaham]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ricaurte]]></surname>
<given-names><![CDATA[GA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; &#8220;ecstasy&#8221;): a controlled study in humans]]></article-title>
<source><![CDATA[Neuropsychopharmacology]]></source>
<year>1994</year>
<volume>10</volume>
<page-range>129-38</page-range></nlm-citation>
</ref>
<ref id="B209">
<label>209</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCann]]></surname>
<given-names><![CDATA[UD]]></given-names>
</name>
<name>
<surname><![CDATA[Szabo]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Scheffel]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Dannals]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Ricaurte]]></surname>
<given-names><![CDATA[GA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Positron emission tomographic evidence of toxic effect of MDMA (&#8220;ecstasy&#8221;) on brain serotonin neurons in human beings]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1998</year>
<volume>352</volume>
<page-range>1433-7</page-range></nlm-citation>
</ref>
<ref id="B210">
<label>210</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ricaurte]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[McCann]]></surname>
<given-names><![CDATA[UD]]></given-names>
</name>
<name>
<surname><![CDATA[Szabo]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Scheffel]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toxicodynamics and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine (MDMA, &#8216;ecstasy&#8217;).]]></article-title>
<source><![CDATA[Toxicol Lett]]></source>
<year>2000</year>
</nlm-citation>
</ref>
<ref id="B211">
<label>211</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Semple]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Ebmeier]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
<name>
<surname><![CDATA[Glabus]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[O'Carroll]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Johnstone]]></surname>
<given-names><![CDATA[EC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (&#8216;ecstasy&#8217;) users]]></article-title>
<source><![CDATA[Br J Psychiatry]]></source>
<year>1999</year>
<volume>175</volume>
<page-range>63-9.</page-range></nlm-citation>
</ref>
<ref id="B212">
<label>212</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ernst]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Grob]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Poland]]></surname>
<given-names><![CDATA[RE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cerebral (1)H MRS alterations in recreational 3,4-methylenedioxymethamphetamine (MDMA, &#8216;ecstasy&#8217;) users.]]></article-title>
<source><![CDATA[J Magn Reson Imaging]]></source>
<year>1999</year>
<volume>10</volume>
<page-range>521-6.</page-range></nlm-citation>
</ref>
<ref id="B213">
<label>213</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Grob]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Ernst]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Itti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mishkin]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
<name>
<surname><![CDATA[Jose-Melchor]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study]]></article-title>
<source><![CDATA[Psychiatry Res]]></source>
<year>2000</year>
<volume>98</volume>
<page-range>15-28</page-range></nlm-citation>
</ref>
<ref id="B214">
<label>214</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Obrocki]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Buchert]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Vaterlein]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Thomasius]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Beyer]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Schiemann]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ecstasy - long-term effects on the human cen-tral nervous system revealed by positron emission tomography]]></article-title>
<source><![CDATA[Br J Psychiatry]]></source>
<year>1999</year>
<volume>175</volume>
<page-range>186-8</page-range></nlm-citation>
</ref>
<ref id="B215">
<label>215</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dafters]]></surname>
<given-names><![CDATA[RI]]></given-names>
</name>
<name>
<surname><![CDATA[Duffy]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[O'Donnell]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bouquet]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Level of use of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) in humans correlates with EEG power and coherence.]]></article-title>
<source><![CDATA[Psychopharmacology]]></source>
<year>1999</year>
<volume>145</volume>
<page-range>82-90</page-range></nlm-citation>
</ref>
<ref id="B216">
<label>216</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tuchtenhagen]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Daumann]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Norra]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gobbele]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Becker]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pelz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High intensity dependence of auditory evoked dipole source activity indicates decreased serotonergic activity in abstinent ecstasy (MDMA) users]]></article-title>
<source><![CDATA[Neuropsychopharmacolo-gy]]></source>
<year>2000</year>
<volume>22</volume>
<page-range>608-17</page-range></nlm-citation>
</ref>
<ref id="B217">
<label>217</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campkin]]></surname>
<given-names><![CDATA[N.T.]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[U.M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Another death from Ecstacy]]></article-title>
<source><![CDATA[J R Soc Med]]></source>
<year>1992</year>
<volume>85</volume>
<page-range>61</page-range></nlm-citation>
</ref>
<ref id="B218">
<label>218</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schifano]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Oyefeso]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Corkery]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Cobain]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Jambert-Gray]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Martinotti]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Ghodse]]></surname>
<given-names><![CDATA[A.H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002.]]></article-title>
<source><![CDATA[Hum Psychopharmacol]]></source>
<year>2003</year>
<volume>18</volume>
<page-range>519-24</page-range></nlm-citation>
</ref>
<ref id="B219">
<label>219</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jonas]]></surname>
<given-names><![CDATA[M.M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 6-2001. A 17-year-old girl with marked jaundice and weight loss.]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2001</year>
<volume>344</volume>
<page-range>591-9</page-range></nlm-citation>
</ref>
<ref id="B220">
<label>220</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reneman]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Majoie]]></surname>
<given-names><![CDATA[C.B.]]></given-names>
</name>
<name>
<surname><![CDATA[Schmand]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[van den Brink]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[den Heeten]]></surname>
<given-names><![CDATA[G.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prefrontal N-acetylaspartate is strongly associ-ated with memory performance in (abstinent) ecstasy users: preliminary report]]></article-title>
<source><![CDATA[Biol Psychiatry]]></source>
<year>2001</year>
<volume>50</volume>
<page-range>550-554.</page-range></nlm-citation>
</ref>
<ref id="B221">
<label>221.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hays]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proton nuclear magnetic resonance spectroscopy (NMR) methods for determining the purity of reference drug standards and illicit forensic drug seizures.]]></article-title>
<source><![CDATA[J Forensic Sci.]]></source>
<year>2005</year>
<volume>50</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1342-60</page-range></nlm-citation>
</ref>
<ref id="B222">
<label>222.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Deursen]]></surname>
<given-names><![CDATA[M. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Lock]]></surname>
<given-names><![CDATA[E. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Portman-van der Neer]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Organic impurity profiling of 3,4-methylenedioxymethamphetamine (MDMA) tablets seized in The Netherlands]]></article-title>
<source><![CDATA[J.; Sci. Justice]]></source>
<year>2006</year>
<volume>46</volume>
</nlm-citation>
</ref>
<ref id="B223">
<label>223</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[R. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Kovar]]></surname>
<given-names><![CDATA[K. A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Forensic Sci. Int.]]></source>
<year>2003</year>
<volume>134</volume>
<page-range>187-95</page-range></nlm-citation>
</ref>
<ref id="B224">
<label>224</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hays]]></surname>
<given-names><![CDATA[P. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[R. A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Magn. Reson. Chem]]></source>
<year>2009</year>
</nlm-citation>
</ref>
<ref id="B225">
<label>225.</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malz]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Jancke]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<source><![CDATA[J. Pharm. Biomed. Anal.]]></source>
<year>2005</year>
<volume>38</volume>
<page-range>813-23</page-range></nlm-citation>
</ref>
<ref id="B226">
<label>226</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dowling]]></surname>
<given-names><![CDATA[G.P.]]></given-names>
</name>
<name>
<surname><![CDATA[McDonough]]></surname>
<given-names><![CDATA[E.T.]]></given-names>
</name>
<name>
<surname><![CDATA[Bost]]></surname>
<given-names><![CDATA[R.O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eve&#8221; and &#8220;ecstasy&#8221;: a report of five deaths associated with the use of MDEA and MDMA.]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1987</year>
<volume>257</volume>
<page-range>1615-1617.</page-range></nlm-citation>
</ref>
<ref id="B227">
<label>227</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gill]]></surname>
<given-names><![CDATA[J.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Hayes]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[deSouza]]></surname>
<given-names><![CDATA[I.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Marker]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Stajic]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ecstasy (MDMA) deaths in New York City: a case series and review of the literature]]></article-title>
<source><![CDATA[J Forensic Sci]]></source>
<year>2002</year>
<volume>47</volume>
<page-range>121-6</page-range></nlm-citation>
</ref>
<ref id="B228">
<label>228</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Libiseller]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Pavlic]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Grubwieser]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Rabl]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ecstasy-deadly risk even outside rave parties.]]></article-title>
<source><![CDATA[Forensic Sci Int]]></source>
<year>2005</year>
<volume>153</volume>
<page-range>227-30</page-range></nlm-citation>
</ref>
<ref id="B229">
<label>229</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caballero]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez-Navidad]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Cotorruelo]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Txoperena]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ecstasy-induced brain death and acute hepatocellular fail-ure: multiorgan donor and liver transplantation]]></article-title>
<source><![CDATA[Transplantation]]></source>
<year>2002</year>
<volume>74</volume>
<page-range>532-7</page-range></nlm-citation>
</ref>
<ref id="B230">
<label>230</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Carlis]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[De Gasperi]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Slim]]></surname>
<given-names><![CDATA[A.O.]]></given-names>
</name>
<name>
<surname><![CDATA[Giacomoni]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Corti]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Mazza]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Di Benedetto]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Lauterio]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Arcieri]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Maione]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Rondinara]]></surname>
<given-names><![CDATA[G.F.]]></given-names>
</name>
<name>
<surname><![CDATA[Forti]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Liver transplantation for ecstasy-induced fulminant hepatic failure]]></article-title>
<source><![CDATA[Transplant Proc]]></source>
<year>2001</year>
<volume>33</volume>
<page-range>2743-4</page-range></nlm-citation>
</ref>
<ref id="B231">
<label>231</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garbino]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Mentha]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Romand]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ecstasy ingestion and fulminant hepatic failure: liver transplantation to be considered as a last therapeutic option]]></article-title>
<source><![CDATA[Vet Hum Toxicol]]></source>
<year>2001</year>
<page-range>99-102</page-range></nlm-citation>
</ref>
<ref id="B232">
<label>232.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gouzoulis-Mayfrank]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hermle]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kovar]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Sass]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Die Entaktogene &#8220;ecstasy&#8221; (MDMA), &#8220;eve&#8221; (MDEA) und andere ringsubstituirte Methamphetaminderivate]]></article-title>
<source><![CDATA[Eine neue Stoffklasse unter den illegalen Designerdro-gen? Nervenarz]]></source>
<year>1996</year>
<volume>67</volume>
<page-range>369-80</page-range></nlm-citation>
</ref>
<ref id="B233">
<label>233</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christophersen]]></surname>
<given-names><![CDATA[AS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[mphetamine designer drugs - an overview and epidemiology.]]></article-title>
<source><![CDATA[Toxicol Lett]]></source>
<year>2000</year>
<page-range>127-31</page-range></nlm-citation>
</ref>
<ref id="B234">
<label>234</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shulgin]]></surname>
<given-names><![CDATA[AT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The background and chemistry of MDMA]]></article-title>
<source><![CDATA[J Psychoactive Drugs]]></source>
<year>1986</year>
<volume>18</volume>
</nlm-citation>
</ref>
<ref id="B235">
<label>235</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenbaum]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ecstasy: America's new "reefer madness".]]></article-title>
<source><![CDATA[J Psychoactive Drugs]]></source>
<year>2002</year>
<volume>34</volume>
</nlm-citation>
</ref>
<ref id="B236">
<label>236</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vollenweider]]></surname>
<given-names><![CDATA[F.X.]]></given-names>
</name>
<name>
<surname><![CDATA[Gamma]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Liechti]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Huber]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psychological and cardiovascular effects and short-term sequelae of MDMA (&#8220;ecstasy&#8221;) in MDMA-naive healthy volunteers]]></article-title>
<source><![CDATA[Neuropsychopharmacology]]></source>
<year>1998</year>
<volume>19</volume>
<page-range>241-51</page-range></nlm-citation>
</ref>
<ref id="B237">
<label>237</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saguil]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psychological and pharmacologic treatments for adults with PTSD]]></article-title>
<source><![CDATA[Am Fam Physician]]></source>
<year>2019</year>
<volume>99:</volume>
<page-range>577&#8208;583</page-range></nlm-citation>
</ref>
<ref id="B238">
<label>238</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O&#8217;Neil]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McDonagh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cheney]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Carlson]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Holmes]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacologic and nonpharmacologic treatments for posttraumatic stress disorder: groundwork for a publicly available repository of randomized controlled trial data]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B239">
<label>239</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mithoefer]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Mithoefer]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Jerome]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Doblin]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.]]></article-title>
<source><![CDATA[J Psychopharmacol]]></source>
<year>2011</year>
<volume>25</volume>
<page-range>439-52</page-range></nlm-citation>
</ref>
<ref id="B240">
<label>240</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mithoefer]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Mithoefer]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Feduccia]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Jerome]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wymer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a ran-domised, double-blind, dose-response, phase 2 clinical trial]]></article-title>
<source><![CDATA[Lancet Psychiatry]]></source>
<year>2018</year>
<volume>5</volume>
<page-range>486-97</page-range></nlm-citation>
</ref>
<ref id="B241">
<label>241</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ot&#8217;alora]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Grigsby]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Poulter]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[3rd]]></surname>
<given-names><![CDATA[Van Derveer JW]]></given-names>
</name>
<name>
<surname><![CDATA[Giron]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Jerome]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized phase 2 controlled trial]]></article-title>
<source><![CDATA[J Psychopharmacol]]></source>
<year>2018</year>
<volume>32</volume>
<page-range>1295-307</page-range></nlm-citation>
</ref>
<ref id="B242">
<label>242</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bedi]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[,4-methylenedioxymethamphetamine as a psychiatric treatment.]]></article-title>
<source><![CDATA[JAMA Psychiatry]]></source>
<year>2018</year>
<volume>75</volume>
<page-range>419-20</page-range></nlm-citation>
</ref>
<ref id="B243">
<label>243</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yazar-Klosinski]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
<name>
<surname><![CDATA[Mithoefer]]></surname>
<given-names><![CDATA[MC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential psychiatric uses for MDMA]]></article-title>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>2017</year>
<volume>101</volume>
<page-range>194-6</page-range></nlm-citation>
</ref>
<ref id="B244">
<label>244</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yazar Klosinski]]></surname>
<given-names><![CDATA[Berra]]></given-names>
</name>
<name>
<surname><![CDATA[Mitchell]]></surname>
<given-names><![CDATA[Jennifer]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Randomized Double-Blind, Placebo Controlled Phase 3 Study Assessing Efficacy and Safety of MDMA-Assisted Therapy for the Treatment of Severe PTSD.]]></article-title>
<source><![CDATA[Biol. Psychiatry]]></source>
<year>2021</year>
<volume>89</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B245">
<label>245</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thal]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Lommen]]></surname>
<given-names><![CDATA[MJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current perspective on MDMA-assisted psychotherapy for posttraumatic stress disorder.]]></article-title>
<source><![CDATA[J Con-temp Psychother]]></source>
<year>2018</year>
<volume>48</volume>
<page-range>99-108</page-range></nlm-citation>
</ref>
<ref id="B246">
<label>246.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kamilar-Britt]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bedi]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): controlled studies in humans and laboratory animals.]]></article-title>
<source><![CDATA[Neurosci Biobehav Rev.]]></source>
<year>2015</year>
<volume>57</volume>
<page-range>433-46</page-range></nlm-citation>
</ref>
<ref id="B247">
<label>247.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Ferguson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Morgan]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of ecstasy on cooperative behaviour and perception of trustworthiness: a naturalistic study]]></article-title>
<source><![CDATA[J Psychopharmacol]]></source>
<year>2014</year>
<volume>28</volume>
<page-range>1001-8</page-range></nlm-citation>
</ref>
<ref id="B248">
<label>248</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oehen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Traber]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Widmer]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized, controlled pilot study of MDMA (+/- 3,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD).]]></article-title>
<source><![CDATA[J Psychopharmacol]]></source>
<year>2013</year>
<volume>27</volume>
<page-range>40-52</page-range></nlm-citation>
</ref>
<ref id="B249">
<label>249</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feduccia]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Holland]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mithoefer]]></surname>
<given-names><![CDATA[MC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progress and promise for the MDMA drug development program]]></article-title>
<source><![CDATA[Psychopharma-cology]]></source>
<year>2018</year>
<volume>235</volume>
<page-range>561-71</page-range></nlm-citation>
</ref>
<ref id="B250">
<label>250</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Mithoefer]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Mithoefer]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic effect of increased openness: investigating mechanism of action in MDMA-assisted psychotherapy]]></article-title>
<source><![CDATA[J Psychopharmacol]]></source>
<year>2017</year>
<volume>31</volume>
<page-range>967-74</page-range></nlm-citation>
</ref>
<ref id="B251">
<label>251</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yazar-Klosinski]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
<name>
<surname><![CDATA[Mithoefer]]></surname>
<given-names><![CDATA[MC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential psychiatric uses for MDMA.]]></article-title>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>2017</year>
<volume>101</volume>
<page-range>194-6</page-range></nlm-citation>
</ref>
<ref id="B252">
<label>252</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bouso]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Doblin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Farre]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder.]]></article-title>
<source><![CDATA[J Psychoactive Drugs]]></source>
<year>2008</year>
<volume>40</volume>
<page-range>225-36</page-range></nlm-citation>
</ref>
<ref id="B253">
<label>253</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Andero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ressler]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[3,4-Methylenedioxymethamphetamine facilitates fear extinction learning.]]></article-title>
<source><![CDATA[Transl Psychiatry]]></source>
<year>2015</year>
<volume>5</volume>
</nlm-citation>
</ref>
<ref id="B254">
<label>254</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amoroso]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Workman]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: a preliminary meta-analysis and comparison to prolonged exposure therapy]]></article-title>
<source><![CDATA[J Psychopharmacol]]></source>
<year>2016</year>
<volume>30</volume>
<page-range>595-600</page-range></nlm-citation>
</ref>
<ref id="B255">
<label>255</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Doss]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Weafer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gallo]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MDMA impairs both the encoding and retrieval of emotional recollections]]></article-title>
<source><![CDATA[Neuro-psychopharmacology]]></source>
<year>2018</year>
<volume>43</volume>
<page-range>791-800</page-range></nlm-citation>
</ref>
<ref id="B256">
<label>256.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jerome]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Schuster]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yazar-Klosinski]]></surname>
<given-names><![CDATA[BB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Can MDMA play a role in the treatment of substance abuse?]]></article-title>
<source><![CDATA[Curr Drug Abuse Rev.]]></source>
<year>2013</year>
<volume>6:</volume>
<page-range>54-62</page-range></nlm-citation>
</ref>
<ref id="B257">
<label>257</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mithoefer]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Mithoefer]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.]]></article-title>
<source><![CDATA[J Psychopharmacol]]></source>
<year>2013</year>
<volume>27</volume>
<page-range>28-39</page-range></nlm-citation>
</ref>
<ref id="B258">
<label>258</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[CM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[3,4-Methylenedioxymethamphetamine's (MDMA's) impact on posttraumatic stress disorder]]></article-title>
<source><![CDATA[Ann Pharmacot-her]]></source>
<year>2014</year>
<volume>48</volume>
<page-range>908-15</page-range></nlm-citation>
</ref>
<ref id="B259">
<label>259</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amoroso]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The psychopharmacology of +/-3,4 methylenedioxymethamphetamine and its role in the treatment of post-traumatic stress disorder.]]></article-title>
<source><![CDATA[J Psychoactive Drugs.]]></source>
<year>2015</year>
<volume>47</volume>
<page-range>337-344.</page-range></nlm-citation>
</ref>
<ref id="B260">
<label>260</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Titheradge]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MDMA for the treatment of mood disorder: all talk no substance?]]></article-title>
<source><![CDATA[Ther Adv Psychopharmacol.]]></source>
<year>2015</year>
<volume>5</volume>
<page-range>179-88</page-range></nlm-citation>
</ref>
<ref id="B261">
<label>261</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Danforth]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Struble]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Yazar-Klosinski]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MDMA-assisted therapy: a new treatment model for social anxiety in autistic adults.]]></article-title>
<source><![CDATA[Prog Neuropsychopharmacol Biol Psychiatry]]></source>
<year>2016</year>
<volume>64</volume>
<page-range>237-49</page-range></nlm-citation>
</ref>
<ref id="B262">
<label>262</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sessa]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Why psychiatry needs 3,4-methylenedioxymethamphetamine: a child psychiatrist's perspective]]></article-title>
<source><![CDATA[Neurotherapeutics]]></source>
<year>2017</year>
<volume>14</volume>
<page-range>741-9</page-range></nlm-citation>
</ref>
<ref id="B263">
<label>263</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johansen]]></surname>
<given-names><![CDATA[PO]]></given-names>
</name>
<name>
<surname><![CDATA[Krebs]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale]]></article-title>
<source><![CDATA[J Psychophar-macol]]></source>
<year>2009</year>
<volume>23</volume>
<page-range>389-91</page-range></nlm-citation>
</ref>
<ref id="B264">
<label>264</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heifets]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Malenka]]></surname>
<given-names><![CDATA[RC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MDMA as a probe and treatment for social behaviors]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2016</year>
<volume>166</volume>
<page-range>269-72</page-range></nlm-citation>
</ref>
<ref id="B265">
<label>265</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sessa]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Why MDMA therapy for alcohol use disorder? And why now?]]></article-title>
<source><![CDATA[Neuropharmacology]]></source>
<year>2017</year>
<page-range>83-8</page-range></nlm-citation>
</ref>
<ref id="B266">
<label>266</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murnane]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Fantegrossi]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
<name>
<surname><![CDATA[Godfrey]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys]]></article-title>
<source><![CDATA[J Pharmacol Exp Ther.]]></source>
<year>2010</year>
<volume>334</volume>
<page-range>642-50</page-range></nlm-citation>
</ref>
<ref id="B267">
<label>267</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pitts]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
<name>
<surname><![CDATA[Curry]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Hampshire]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[(+/-)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA.]]></article-title>
<source><![CDATA[Psychopharmacology]]></source>
<year>2018</year>
<volume>235</volume>
<page-range>377-92</page-range></nlm-citation>
</ref>
<ref id="B268">
<label>268</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Curry]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Tran]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Separating the agony from ecstasy: R(-)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice.]]></article-title>
<source><![CDATA[Neuropharmacology]]></source>
<year>2018</year>
<volume>128</volume>
<page-range>196-206</page-range></nlm-citation>
</ref>
<ref id="B269">
<label>269</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fantegrossi]]></surname>
<given-names><![CDATA[WE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reinforcing effects of methylenedioxy amphetamine congeners in rhesus monkeys: are intravenous self-administration experiments relevant to MDMA neurotoxicity?]]></article-title>
<source><![CDATA[Psychopharmacology]]></source>
<year>2007</year>
<volume>189</volume>
<page-range>471-82</page-range></nlm-citation>
</ref>
<ref id="B270">
<label>270</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Woolverton]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimating the relative reinforcing strength of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) and its isomers in rhesus monkeys: comparison to (+)-methamphetamine]]></article-title>
<source><![CDATA[Psychopharmacology]]></source>
<year>2007</year>
<volume>189</volume>
<page-range>483-8</page-range></nlm-citation>
</ref>
<ref id="B271">
<label>271</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fantegrossi]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
<name>
<surname><![CDATA[Ullrich]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Rice]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoiso-mers as reinforcers in rhesus monkeys: serotonergic involvement]]></article-title>
<source><![CDATA[Psychopharmacology]]></source>
<year>2002</year>
</nlm-citation>
</ref>
<ref id="B272">
<label>272.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buchert]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Thomasius]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Wilke]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Peterson]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Nebeling]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Obrocki]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Schulze]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
<name>
<surname><![CDATA[Clausen]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A voxel-based PET investigation of the long-term effects of &#8216;ecstasy&#8217; consumption on brain serotonin transporters.]]></article-title>
<source><![CDATA[Am J Psychiatry]]></source>
<year>2004</year>
<volume>161</volume>
<page-range>1181-1189.</page-range></nlm-citation>
</ref>
<ref id="B273">
<label>273</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhattachary]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Powell]]></surname>
<given-names><![CDATA[J.H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or &#8220;ecstasy&#8221;: evidence for cognitive impairment.]]></article-title>
<source><![CDATA[Psychol Med]]></source>
<year>2001</year>
<volume>31</volume>
<page-range>647-58</page-range></nlm-citation>
</ref>
<ref id="B274">
<label>274</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bedi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Phan]]></surname>
<given-names><![CDATA[K.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Angstadt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[de Wit]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of MDMA on sociability and neural response to social threat and social reward.]]></article-title>
<source><![CDATA[Psychopharmacology]]></source>
<year></year>
<volume>207</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>73-83</page-range></nlm-citation>
</ref>
<ref id="B275">
<label>275</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[R.L. Carhart-Harris]]></surname>
<given-names><![CDATA[M.B. Wall]]></given-names>
</name>
<name>
<surname><![CDATA[D. Erritzoe]]></surname>
<given-names><![CDATA[M. Kaelen]]></given-names>
</name>
<name>
<surname><![CDATA[B. Ferguson]]></surname>
<given-names><![CDATA[I. De Meer]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories.]]></article-title>
<source><![CDATA[Int. J. Neuropsychophar-macol.]]></source>
<year>2014</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>527-40</page-range></nlm-citation>
</ref>
<ref id="B276">
<label>276</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Snell]]></surname>
<given-names><![CDATA[Richard S]]></given-names>
</name>
</person-group>
<source><![CDATA[Neuroanatomía Clínica]]></source>
<year>2014</year>
<edition>Séptima</edition>
<page-range>626-41</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Wolters Kluers Health]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B277">
<label>277</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Snell]]></surname>
<given-names><![CDATA[Richard S.]]></given-names>
</name>
</person-group>
<source><![CDATA[Neuroanatomía Clínica. T Capítulo 08: Estructura y localización funcional de la corteza cerebral.]]></source>
<year>2014</year>
<edition>Séptima</edition>
<page-range>479-514</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Wolters Kluers Health]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B278">
<label>278</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paulsen]]></surname>
<given-names><![CDATA[Friedrich]]></given-names>
</name>
<name>
<surname><![CDATA[Waschke.]]></surname>
<given-names><![CDATA[Jens]]></given-names>
</name>
</person-group>
<source><![CDATA[Atlas of Anatomy Sobotta: Head, Neck and Neuroanatomy. Capítulo 12: Brain and Spinal Cord.]]></source>
<year>2018</year>
<edition>Décimo sexta</edition>
<page-range>257-440</page-range><publisher-loc><![CDATA[Munich, Alemanina ]]></publisher-loc>
<publisher-name><![CDATA[El Sevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B279">
<label>279</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Snell]]></surname>
<given-names><![CDATA[Richard S.]]></given-names>
</name>
</person-group>
<source><![CDATA[Neuroanatomía Clínica. T Capítulo 07: El Cerebro]]></source>
<year>2014</year>
<edition>Séptima</edition>
<page-range>428-78</page-range><publisher-loc><![CDATA[Espa-ña ]]></publisher-loc>
<publisher-name><![CDATA[Wolters Kluers Health]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B280">
<label>280</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ricaurte]]></surname>
<given-names><![CDATA[G.A.]]></given-names>
</name>
<name>
<surname><![CDATA[McCann]]></surname>
<given-names><![CDATA[U.D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Experimental studies on 3,4-methylenedioxymethamohetamine (MDA, &#8220;ectasy&#8221;) and its potential to damage brain serotonin neurons]]></article-title>
<source><![CDATA[Neurotox Res]]></source>
<year>2001</year>
<volume>3</volume>
<page-range>85-99.</page-range></nlm-citation>
</ref>
<ref id="B281">
<label>281</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCann]]></surname>
<given-names><![CDATA[U.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Szabo]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Scheffel]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
<name>
<surname><![CDATA[Dannals]]></surname>
<given-names><![CDATA[R.F.]]></given-names>
</name>
<name>
<surname><![CDATA[Ricaurte]]></surname>
<given-names><![CDATA[G.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Positron emission tomographic evidence of toxic effect of MDMA (&#8220;ectasy&#8221;) on brain serotonin neurons in human beings]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1998</year>
<volume>352</volume>
<page-range>1433-7</page-range></nlm-citation>
</ref>
<ref id="B282">
<label>282</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reneman]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Lavalaye]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Schmand]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[de Wolff]]></surname>
<given-names><![CDATA[F.A.]]></given-names>
</name>
<name>
<surname><![CDATA[van den Brink]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[den Heeten]]></surname>
<given-names><![CDATA[G.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Booij]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or &#8220;ecstasy&#8221;): preliminary findings.]]></article-title>
<source><![CDATA[Arch Gen Psychiatry]]></source>
<year>2001</year>
<volume>58</volume>
<page-range>901-6</page-range></nlm-citation>
</ref>
<ref id="B283">
<label>283</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piper]]></surname>
<given-names><![CDATA[B.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A developmental comparison of the neurobehavioral effects of ectasy (MDMA).]]></article-title>
<source><![CDATA[Neurotoxicol Teratol]]></source>
<year>2007</year>
<volume>29</volume>
<page-range>288-300</page-range></nlm-citation>
</ref>
<ref id="B284">
<label>284</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allison]]></surname>
<given-names><![CDATA[A. Fedducia]]></given-names>
</name>
<name>
<surname><![CDATA[Michael]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mithoefer. MDMA-assistend psycotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?. Prog. Neuropsychopharmacol.]]></article-title>
<source><![CDATA[Biol. Psychiatry PROG NEURO-PSYCHOPH]]></source>
<year></year>
<page-range>221-8</page-range></nlm-citation>
</ref>
<ref id="B285">
<label>285</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fitzgerakd]]></surname>
<given-names><![CDATA[P.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Seemann]]></surname>
<given-names><![CDATA[J.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Maren]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Can fear extinction be enhanced? A review of farmacological and behavioral findings.]]></article-title>
<source><![CDATA[Brain Res. Bull]]></source>
<year>2014</year>
<volume>105</volume>
<page-range>46-60</page-range></nlm-citation>
</ref>
<ref id="B286">
<label>286</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[R.L. Carhart Harris]]></surname>
<given-names><![CDATA[K. Murphy]]></given-names>
</name>
<name>
<surname><![CDATA[R. Leech]]></surname>
<given-names><![CDATA[D. Erritzoe]]></given-names>
</name>
<name>
<surname><![CDATA[M.B. Wall]]></surname>
<given-names><![CDATA[B. Ferguson]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effects of acutely administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin label-ing and blood oxygen level-dependent resting state functional connectivity.]]></article-title>
<source><![CDATA[Biol. Psychiatry]]></source>
<year>2015</year>
<volume>78</volume>
<page-range>554-62</page-range></nlm-citation>
</ref>
<ref id="B287">
<label>287</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gamma]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Buck]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Berthold]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Liechti]]></surname>
<given-names><![CDATA[M.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Vollenweider]]></surname>
<given-names><![CDATA[F.X.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans]]></article-title>
<source><![CDATA[Neuropsychopharmacology]]></source>
<year>2000</year>
<volume>23</volume>
<page-range>388-95</page-range></nlm-citation>
</ref>
<ref id="B288">
<label>288</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[I.C. Walpola]]></surname>
<given-names><![CDATA[T. Nest]]></given-names>
</name>
<name>
<surname><![CDATA[L. Roseman]]></surname>
<given-names><![CDATA[D. Erritzoe]]></given-names>
</name>
<name>
<surname><![CDATA[A. Feilding]]></surname>
<given-names><![CDATA[D.J. Nutt]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Altered insula connectivity under MDMA.]]></article-title>
<source><![CDATA[Neuropsychopharmacology]]></source>
<year>2017</year>
<volume>42</volume>
<page-range>2152-62</page-range></nlm-citation>
</ref>
<ref id="B289">
<label>289</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castellano Arroyo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gisberto Grifo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Capítulo 88, Valoración médico legal del Daño Psíquico. Gisbert Calabuig. Medicina Legal y Toxicología]]></source>
<year>2019</year>
<edition>Séptima</edition>
<page-range>1302-20</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[El Sevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B290">
<label>290</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pla Martínez]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández Jerez]]></surname>
<given-names><![CDATA[A.F.]]></given-names>
</name>
</person-group>
<source><![CDATA[Capítulo 57, Valoración médico legal del Daño Psíquico. Gisbert Calabuig. Medicina Legal y Toxicología]]></source>
<year>2019</year>
<edition>Séptima</edition>
<page-range>879-904</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[El Sevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B291">
<label>291.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pla Martínez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández Jerez]]></surname>
<given-names><![CDATA[A.F.]]></given-names>
</name>
<name>
<surname><![CDATA[López-Rivadulla Lamas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Capítulo 58, Interpretación de los resultados en toxi-cología forense. Gisbert Calabuig. Medicina Legal y Toxicología]]></source>
<year>2019</year>
<edition>Séptima</edition>
<page-range>905-20</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[El Sevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B292">
<label>292</label><nlm-citation citation-type="book">
<source><![CDATA[Trastornos relacionados con sustancias y trastornos adictivos.]]></source>
<year>2014</year>
<edition>Quinta</edition>
<page-range>481-590</page-range><publisher-loc><![CDATA[Arlington ]]></publisher-loc>
<publisher-name><![CDATA[Asociación Americana de Psiquiatría. Manual Diagnóstico y Estadístico de los Trastornos Mentales DSM-5.]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B293">
<label>293</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[Natalia S.]]></given-names>
</name>
<name>
<surname><![CDATA[Benedito]]></surname>
<given-names><![CDATA[Luiz E. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Maldaner]]></surname>
<given-names><![CDATA[Adriano O.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Validated NMR Approach for MDMA Quantification in Ecstasy Tablets.]]></article-title>
<source><![CDATA[J. Braz. Chem. Soc]]></source>
<year>2018</year>
<volume>29</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
